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“Science is never finished. It proceeds by successive approximations, edging closer and closer 
to a complete and accurate understanding of nature, but it is never fully there.” 
 
Carl Sagan 
 
“The scientist is not a person who gives the right answers; he's one who asks the right questions.” 
 
Claude Lévi-Strauss 
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Abstract 
 
Azurin is a 14 kDa protein produced by Pseudomonas aeruginosa which has cytotoxicity 
activity towards human cancer cell lines. Azurin can enter preferentially into cancer cells, 
forming a complex with the tumour suppressor p53, stabilizing it and inducing apoptosis. The 
capacity of migration and invasion is due, in part, to the regulation of adhesion proteins, like P-
cadherin. P-cadherin is over-expressed in 30% of breast cancers and it is a marker of poor 
survival. Therefore, P-cadherin is a potential therapeutic target in breast cancer. For that 
reason, azurin was used to target P-cadherin, decreasing its level in P-cadherin over-expressing 
breast cancer models and membranar localisation. However, the mechanism of action of azurin 
is not well known. On the other hand, lung cancer has similar signalling pathways associated 
with adhesion, and therefore, this work also focuses on the impact of azurin in lung cancer. Not 
much is known about how the stromal microenvironment at metastasis sites provides a suitable 
home to tumour cells. It is important to study the interaction between metastatic cells and ECM. 
We treated different cancer cells models with azurin (50 µM and 100 µM): four breast cancer 
cell lines with distinct levels of P-cadherin expression and different invasive capacities (MCF-
7/AZ.Mock, MCF-7/AZ.Pcad, SUM149 and BT-20) and one non-small cell lung cancer cell line 
(A549). We investigated the effect of azurin in cell adhesion with different ECM components 
(laminin-332, collagen type-I, fibronectin and collagen type-IV) and we also investigated integrin 
subunits (α6, β1 and β4) expression by western blot.  The azurin effects were also evaluated by 
others parameters, such as ROS measurement, immunocytochemistry, gelatine zymography to 
evaluate MMP-2 activity and invasion capacity. 
Azurin decreased integrin subunits (α6, β1 and β4) in all studied models (breast and lung 
cancer), more consistently in the integrin subunit β1. Moreover, azurin decreased adhesion to 
ECM components, with more significance in collagen and laminin (breast cancer) and 
fibronectin (lung cancer), both main components in each cancer type. In BT-20 and A549, 
azurin decreased MMP-2 activity and the invasion through Matrigel
TM
. All these results 
corroborate azurin as potential cancer therapeutic drug. 
 
Funded project: 
Bacterial protein azurin as a new candidate drug to treat poor-prognosis breast cancer, 
PTDC/EBB-BIO/100326/2008, PI: Arsénio M. Fialho 
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Resumo 
 
A azurina é uma proteína de 14 kDa produzida por Pseudomonas aeruginosa, com 
actividade citotóxica em linhas celulares cancerígenas humanas. A azurina entra 
preferencialmente em células cancerígenas, formando um complexo com a proteína supressora 
tumoral p53, estabilizando-a e induzindo a apoptose. A capacidade de migração e invasão 
deve-se, em parte, à regulação de proteínas de adesão celular, como a P-caderina. A P-
caderina é sobre-expressa em 30% dos cancros de mama e é um marcador de mau 
prognóstico. Por isso, a P-caderina é um potencial alvo terapêutico em cancro de mama. Por 
essa razão, a capacidade da azurina diminuir esta proteína em modelos de cancro de mama 
que sobre-expressam P-caderina foi testada, verificando-se que a azurina diminui a sua 
expressão proteica e localização membranar. No entanto, o mecanismo de acção da azurina 
não é ainda bem conhecido. Por outro lado, o cancro do pulmão tem vias de sinalização 
semelhantes associadas à adesão celular, e por isso, este trabalho também se foca no impacto 
da azurina no cancro de pulmão. Não se sabe muito sobre como o microambiente estromal em 
locais de metástase fornece um ambiente adequado para as células tumorais. É por isso 
importante estudar a interação entre células metastáticas e o meio extracelular. 
Diferentes linhas celulares de cancro de mama com níveis distintos de expressão de P-
caderina e diferentes capacidades invasivas (MCF-7/AZ.Mock, MCF-7/AZ.Pcad, SUM149, BT- 
20) e de cancro do pulmão (A549) foram tratadas com azurina (50µM e 100µM). O efeito de 
azurina na adesão celular com diferentes componentes do meio extracelular (laminina-332, 
colagénio do tipo-I, fibronectina e colagénio do tipo-IV) foi investigado, bem como a expressão 
de subunidades de integrina (α6, β1 e β4) por western blot. Os efeitos da azurina também foram 
avaliados por outros parâmetros, tais como a medição de ROS, imunocitoquímica, zimografia 
de gelatina de modo a avaliar a actividade da MMP-2 e a capacidade de invasão. 
A azurina diminui a expressão das subunidades de integrina (α6, β1 e β4) em todos os 
modelos estudados (cancro de mama e de pulmão), de forma mais consistente na subunidade 
de integrina β1. Além disso, a azurina diminui a adesão celular a componentes da matriz 
extracelular, principalmente em colagénio e laminina (cancro da mama) e fibronectina (cancro 
de pulmão), os componentes principais de cada tipo de cancro. Em BT-20 e A549, a azurina 
diminui a actividade da MMP-2 e, consequentemente, a capacidade de invasão. Estes 
resultados confirmam a azurina como um potencial fármaco terapêutico no cancro. 
 
Projecto financiado: 
Bacterial protein azurin as a new candidate drug to treat poor-prognosis breast cancer, 
PTDC/EBB-BIO/100326/2008, PI: Arsénio M. Fialho 
 
Colaboração: 
Este projeto está a ser executado em colaboração com Dr. Joana Paredes e Dr. Raquel 
Seruca, IPATIMUP, Portugal. 
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1. Azurin and cancer 
 
1.1. Bacterial protein azurin 
 
In 1890, William B. Coley described for the first time bacteria as anticancer agents. Not only 
live bacteria have applications in cancer therapies, but also bacteria-derived products 
(Bernardes et al., 2010). Pseudomonas aeruginosa (P. aeruginosa) produces a potent virulence 
factor, called exotoxin A, that is a promising anticancer agent (Wolf & Elsässer-Beile, 2009). P. 
aeruginosa also produces at least two more cytotoxic proteins against cancer cells: cytochrome 
c551 and azurin (Figure 1) (Bernardes et al., 2010). 
 
 
Figure 1: Three dimensions structure of azurin from P. aeruginosa (PDB_1JZG) 
 
Azurin is a water soluble, low molecular weight copper-containing redox protein. The 
presence of a copper ion in the polypeptide chain contributes to azurin stability (Ramachandran 
et al., 2011). This molecule, with 128 amino acids and 14 kDa, is involved in the electron 
transport chain (Bernardes et al., 2010), during denitrification by P. aeruginosa. Azurin has very 
different targets and is designated as “anticapavi” agent (Fialho et al., 2007), since other human 
diseases can be targeted by this protein. 
Laz, a modified form of azurin, was characterized from gonococci and meningococci, such 
as Neisseria meningitidis, which can cause meningitis, an inflammation of the brain meninges. 
This surface-exposed Neisserial azurin has an extra epitope (39 amino acids) in the N-terminal 
called H.8 (Hong et al., 2006; Yamada et al., 2005). This lipidated epitope is responsible for 
entry in glioblastoma cells by penetrating blood-brain barrier, an ability that azurin does not 
possess (Hong et al., 2006). H.8 epitope is important for the surface display of Laz but not to its 
cytotoxic capacity, suggesting an important role in disrupting entry barriers to glioblastoma cells 
in brain tumour (Fialho, Gupta, & Chakrabarty, 2008). Azurin and Laz interfere with the growth 
of parasite Plasmodium falciparum, in entry of HIV-1 virus in human cells and breast cancer 
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cells; and exert cytotoxicity in human cancer cells (Fialho et al., 2007). The summary of 
mechanisms of action of azurin and Laz (induction of cell death, prevention of adhesion and 
invasion and growth suppression) is explained in Figure 2. 
 
 
Figure 2: Azurin and Laz as novel drug candidates effective against cancers and infectious 
agents, such as HIV-1 virus, P. falciparum and T. gondii parasites. The mode of action in the 
induction of cell death, prevention of adhesion and invasion, and growth suppression. (Fialho et 
al., 2008). 
 
1.2. Azurin secretion by P. aeruginosa and entry in host cells 
 
Azurin is secreted, out of the periplasmic space of P. aeruginosa, to the outside medium in 
an energy-independent manner, when P. aeruginosa cells are exposed to human cancer cells, 
but less when exposed to normal cells (Mahfouz et al., 2007). Also, azurin enters preferentially 
in human cancer cells compared to normal cells. The preferential entry of azurin in cancer cells 
is mediated by the amino acids 50-77 of the protein, termed p28, which is the protein transport 
domain of azurin. p28 forms an extended amphipathic α-helix with both a hydrophobic amino 
acids (50-66) and hydrophilic amino acids (67-77) (Yamada et al., 2005). The protein 
transduction domain p28 was further refined, by reducing the N-terminal to amino acids 50-67, 
called p18. p18 is the minimal fragment responsible for the preferential entry of azurin into 
10 
 
human cancer cells. The authors showed that the entry of p28 and p18 occurs mainly via a non-
endocytic and without loss of membrane integrity (Taylor et al., 2009). 
Recently, the start-up company CDG Therapeutics has terminated phase I human clinical 
trials of p28 for its anticancer activity (www.clinicaltrials.gov, NCT00914914). This trial 
comprised 15 advanced-stage cancer patients with metastatic and solid tumours (7 melanoma, 
4 colon, 2 sarcoma, 1 pancreatic, and 1 prostate) in patients where the tumours were no longer 
responding to conventional drugs (radiation therapy and temozolomide). When p28 was given 
intravenously, seven patients demonstrated stable disease, three patients showed partial 
regression, one complete response. Very little toxicity was seen even with the highest 
concentration of p28, and three surviving patients has been living disease-free for over 110, 140 
and 158 weeks (Warso et al., 2013). 
 
1.3. Azurin action toward cancer cells 
 
Two main effects of azurin’s action to cancer cells have been described so far: one acts 
through p53/Bax and the other by the Eph receptors family.  Azurin binds to the intracellular 
tumour suppressor p53, stabilizing it and leads to increased expression of pro-apoptotic protein 
Bax and Bax-dependent apoptosis in cancer cells (Figure 3) (Apiyo & Wittung-Stafshede, 2005; 
Yamada et al., 2002a; 2004). It also binds to several Eph receptor tyrosine kinases (RTKs), a 
family of extracellular receptor proteins known to be up-regulated in many tumours; and this 
binding with EphB2 interferes in its phosphorylation at the tyrosine residue, resulting in inhibition 
of cell signalling and cancer growth (Figure 4) (Chaudhari et al., 2007). 
 
1.3.1. Azurin and p53 interaction 
 
p53 is a major tumour suppressor protein that is mutated or inactivated in 50% of human 
cancers (Gabellieri et al., 2011). The first evidence of azurin-p53 interaction came from glycerol 
gradient and column binding (Punj et al., 2003). Later, isothermal titration calorimetry 
demonstrated that four azurin molecules bind per one monomer of p53 with a dissociation 
constant of 33±12 nM, presumably in the p53 N-terminal domain (NTD) (Apiyo & Wittung-
Stafshede, 2005). 
Azurin enters in cancer cells and form a complex with the tumour suppressor protein p53, 
thereby stabilizing this normally labile protein and enhancing its intracellular concentration 
(Fialho et al., 2008). This stabilization of p53 was thought to be due to the binding of azurin 
close to the MDM2-binding site; consequently, MDM2 could not promote p53 ubiquitination. 
However, amino acids 19-26 of p53, the MDM2-binding site, were not detected as a preferred 
binding site for azurin, and, as a result of this, prevention of p53 degradation is through to occur 
through a MDM2-independent pathway (Yamada et al., 2009). Azurin interacts with p53 at the 
level of the trans-activation domain, more exactly with amino acids 1-63 of p53 (Gabellieri et al., 
2011).  Using p18 (amino acids 50-67), p18b (amino acids 60-77) and p12 (amino acids 66-77), 
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it was proved that the maximal binding of p53 occurs within amino acids 60-67 of azurin  
(Yamada et al., 2009). However, this is a controversial issue and there are others opinions and 
suggestions to the binding site of azurin in p53 (Gabellieri et al., 2011). 
Some studies suggest that the complex formation with p53 and generation of reactive 
oxygen species (ROS), rather than azurin redox activity, were important in the cytotoxicity action 
of azurin (Fialho et al., 2008). p53 is not only able to up-regulate pro-apoptotic genes such as 
Bax, caspase-9, and PUMA but also to repress some anti-apoptotic genes like B-cell lymphoma 
2 (Bcl-2). A ratio of Bax to Bcl-2 is important to the fate of the cell in response to death stimuli. 
The average ratio of Bax:Bcl-2 in breast cells treated with azurin was higher than in the 
untreated cells, meaning that azurin increases Bax and decreases Bcl-2 expression, activating 
the caspase-9, which in turn actives caspase-7, and consequently induce apoptosis (Figure 3) 
(Punj et al., 2004). So, azurin applies part of its anticancer activity through induction of p53-
mediated apoptosis (Yamada et al., 2009). Moreover, the increase of p53 level also mediates 
various cellular responses including DNA damage (Ramachandran et al., 2011) and G2-M-arrest 
cells. This last event is triggered by the increase of p21 and p27, which in turn inactivates the 
CDK2-Cyclin A complex, causing the cell cycle arrest (Yamada et al., 2009). 
 
 
Figure 3: The mode of action of azurin mediated by p53 protein in the induction of apoptosis in 
breast cancer cells (Adapted from Bernardes et al., 2010) 
 
In breast cancer cells, it led to statistically significant regression of the tumours, without any 
apparent toxicity to normal cells, suggesting potential application of azurin in cancer therapy 
(Vasu Punj et al., 2004; Yamada et al., 2002a). 
While wild-type azurin bound to the N-terminal of p53, a mutant azurin (M44KM64E azurin, 
where two hydrophobic amino acids were replaced by two polar amino acids within the 
hydrophobic patch) formed a different complex with p53, affecting p53’s oligomerization. The 
wild-type azurin induces apoptosis but little inhibition of cell cycle progression in J774 while the 
M44KM64E mutant causes the reverse effect (Yamada et al., 2004), demonstrating how azurin, 
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based on its hydrophobicity, modulates the nature of p53 complex formation and its 
transcriptional specificity in mammalian cells (Fialho et al., 2008). 
In azurin, amino acids Met-44 and Met-64, located in a hydrophobic patch of the protein, is 
important for the interactions with p53 and their substitutions resulted in altered complex 
formation with p53 (Yamada et al., 2004; 2002b). But only Met-64 is present in the p53-binding 
site of p28 (Yamada et al., 2009). By atomic force microscopy (AFM), p53 was immobilized in a 
gold substrate and azurin was tethered in the AFM tip. The results confirmed the interaction 
between both proteins with an estimated dissociation constant of 6 µM, lower than that 
estimated before. The complex forms between azurin and p53 DNA-binding domain (DBD) was 
investigated. p53 DBD acquires a β-sandwich fold, formed by two antiparallel β-sheets (S1 and 
S11), with 4 and 5 strands, respectively (s1,s2,s3,s8 and s4,s6,s7,s9,s10). This structure is a scaffold 
for two large loops, L2 and L3, and a loop-sheet-helix (LI-SIII-H2). Using Zdock docking program, 
and appealing to some characteristics, the best model of azurin has been chose. It involves L1 
loop (maybe the most flexible region capable of a strong structural adaptation) and strands s7 
and s8 in the p53 DBD binding interface, and the residues in the hydrophobic patch of azurin. 
This flexibility of L1 loop can be one of the reasons for the azurin-induced stability of p53 (Chen 
& Weng, 2002; De Grandis et al., 2007; Taranta et al., 2009).  
The NTD and C-terminal regulatory domain (CTD) are predominantly unstructured under 
normal conditions. The NTD is organized in an α-helix, HI, and two turns assuming another α-
helix structure, HII and HIII, linked by a fragment of 30-32 residues. Using Zdock docking 
program, and appealing to some characteristics, the best model of azurin has been chose. It 
involves the helices HII and HIII of p53, that have a strong adaptation to the azurin shape, 
increasing packing between both proteins, through numerous and favourable Van der Waals 
interactions. Comparing the two best models (DBD p53-azurin and NTD p53-azurin), the latter 
has the best result (lower free energy). For a more detailed review see (Bernardes et al., 2010). 
 
1.3.2. Azurin and Eph receptor interaction 
 
Eph RTKs, like EphB2, are the family of 14 extracellular receptors which bind to ephrins, like 
ephrinB2, known to initiate cell signalling leading to cancer growth (Fialho et al., 2008). Eph-
ephrin interaction induces a series of cellular signalling processes, like proliferation, migration, 
invasion and angiogenesis. Some Eph receptors and ephrin ligands are up-regulated in some 
tumours, like the case of EphB2 which is up-regulated in glioblastoma, hepatocellular 
carcinoma, gastrointestinal and renal carcinomas, and prostate, lung and ovarian cancers. 
Azurin has structural similarities with the ephrinB2 ectodomain and has high values of 
interaction with receptor EphB2 and also EphA6, EphA4 and EphA7. In particular, the fragment 
amino acids 88-113 of azurin, coincident with the G-H loop of ephrinB2-Fc, had a high affinity 
for binding with EphB2 (12 nM), leading to the highest inhibition of cancer growth. This suggests 
that azurin interferes with the EphB2-ephrinB2 binding. Consequently, this interaction could be 
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a way of blocking the signalling process, antagonizing the Eph-ephrin mediated tumour 
progression (Figure 4) (Chaudhari et al., 2007). 
 
 
Figure 4: The mode of action of azurin in the induction of growth inhibition in breast cancer cells 
(Adapted from Bernardes et al., 2010) 
 
1.4. Azurin as a potential breast cancer therapeutic drug 
 
Azurin and p28 are potential breast cancer therapeutics. There are many reasons that 
support this idea. Firstly, both enter preferentially in cancer cells, rather than normal cells. 
Secondly, the four exposed loop regions are believed to be involved in its bindings with other 
proteins. Consequently, the most interesting characteristic of azurin is its ability to bind various 
unrelated mammalian proteins relevant in cancer, conferring on it the property of a natural 
scaffold protein. This also allows the blockage of different signalling cascades that promote 
cancer cell growth, survival and/or invasion. Thirdly, bacterial protein azurin is inexpensive to 
produce (Bernardes et al., 2010), because it can be easily hyper-expressed in E. coli (Fialho et 
al., 2008). Fourthly, because azurin is able to bind to multi-target, it is hard to acquire 
resistance. Fifthly, in vitro and in vivo assays reveal that azurin induces little side effects 
(Bernardes et al., 2010). Sixthly, azurin has a hydrophobic patch and is water soluble which 
should help in its tissue penetration and clearance from the blood stream. Finally, as a bacterial 
protein, azurin could be susceptible to immune attack, but preliminary evidence indicates that 
azurin has low immunogenicity, due to the fact that azurin, a scaffold protein, is a non-antibody 
recognized protein (Fialho et al., 2008). 
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The ability of a single bacterial protein, azurin, to interfere in the growth of cancer, is an 
interesting example of a potential drug candidate that can target multiple unrelated targets, 
interfering in multiple steps in the disease progression. Also, the ability of p28 to act as a vehicle 
to carry cargo proteins inside cancer cells and the ability of azurin to bind many different 
proteins, due to its unique structure features, makes azurin a potentially important natural 
scaffold protein for therapeutic purposes (Bernardes et al., 2010). 
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2. Tumour microenvironment, cancer cell adhesion and invasion 
 
2.1. Normal mammary structure 
 
2.1.1. Mammary epithelium 
 
The mammary gland is a complex interactive network of cells that leads to a proper 
development and functioning. All the interactions with the microenvironment can influence and 
modify the proliferation, survival, polarity, differentiation and invasive capacity of mammary 
epithelial cells (Polyak & Kalluri, 2010). Normal mammary gland contains epithelium and 
stroma. Mammary epithelium  is composed by an inner layer of luminal epithelial cells and outer 
layer of myoepithelial cells (Muschler & Streuli, 2010), which is in contact with the basement 
membrane, a physical barrier separating the epithelial and the stromal compartments (Polyak & 
Kalluri, 2010). 
Mammary epithelium also is source of stem and progenitor cells. There are two models that 
explain the heterogeneity in tumour: “cancer stem cell” model and “clonal evolution” model. The 
first one defends that accumulation of random mutations in stem cells leads to cancer stem cells 
that in turn leads to tumour progression and recurrence. The second one defends that any cells 
(differentiated or undifferentiated) can accumulate mutations leading to tumour formation. 
Breast cancer is enriched in undifferentiated cancer cells that are more aggressive and 
metastatic. Integrin subunits α6 (also known by CD49f) and integrin subunits β1 (also known by 
CD29) are highly expressed in normal stem cells (and low level of CD24). Altogether, those 
markers are able to regenerate a mammary gland. The integrin patterns of cancer stem cells is 
low CD24, high CD29 and low CD61; and cancer progenitor cells is high CD24, low CD29 and 
high CD61. Knowing that, it is important to develop inhibitor of specific integrins, allowing to 
impair self-renewal and differentiation of cancer stem cells (Pontier & Muller, 2009) (Figure 5). 
 
 
Figure 5: Schematic representation of the structure of the mammary epithelium and the 
different integrin heterodimers expressed in luminal epithelial cells and myoepithelial cells 
(Pontier & Muller, 2009) 
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2.1.2. Stroma 
 
Stroma is composed by fibrous connective tissues (Muschler & Streuli, 2010), ECM 
components (collagen type-I, -III and -IV, fibronectin, laminin, proteoglycans) and a variety of 
cell types  like inflammatory/immune cells, endothelial cells and fibroblasts (Gangadhara et al., 
2012); it provides nutrients, blood supply and immune defences (Muschler & Streuli, 2010). The 
ECM is a thick sheet of glycoproteins and proteoglycans, with laminin around (like laminin-111, -
322, -511 and -521) and some cross-linked with collagen type-IV fibrils (Guo & Giancotti, 2004). 
Stromal changes may take place first leading to transformation of epithelial cells (invasion of 
stroma) or transformed epithelia may activate stromal cells in a paracrine way (Gangadhara et 
al., 2012). 
 
2.1.3. Basement membrane 
 
Basement membrane, beyond myoepithelial cells, is in contact with endothelium of the 
vasculature and adipocytes. Basement membrane interacts with mammary epithelial cells 
through integrins, like receptors for collagen (α1β1 and α2β1), laminin-111, -511, -521 (α3β1, α6β1, 
α6β4), laminin-322 (α3β1 and α6β4), fibronectin (α4β1, α5β1 and β3) and vitronectin (α5β1 and β3) 
(Muschler & Streuli, 2010). Cancer cells ted to loss integrins that adhere to the basement 
membrane and maintain or over-express integrins that promote survival, migration, 
proliferations, invasion and metastasis (Guo & Giancotti, 2004). 
The luminal epithelial cells have sialomusin, epithelial specific antigen and occluding in the 
apical membrane; and integrin subunit β4 on the basolateral membrane. This apical-basal 
polarity is observed in luminal epithelial cells grown in Matrigel
TM
 but not in collagen type-I 
(Gudjonsson et al., 2002). However, co-culture with normal myoepithelial cells restores luminal 
epithelial cell polarity even in collagen cultures, in part mediated by laminin-1 secreted by the 
myoepithelial cells. So, cells grown in three-dimension environment can produce unique 
components that sometimes mimic the in vivo conditions (Polyak & Kalluri, 2010). Signalling for 
epithelial polarity is one of the basement membrane’s role in tumour suppression, so it 
gatekeeper function is determinant of cancer progression (Muschler & Streuli, 2010). 
 
2.2. The importance of cancer cell invasion in cancer progression 
 
Invasion is a hallmark of malignant cancer cells. In order to invade, cancer cells must first 
disrupt pre-existing adhesion to other cells, dynamically reorganize their interactions with ECM, 
up-regulate matrix metalloproteinases (MMPs) and alter their cytoskeleton organization 
enhancing their motility (Guarino, 2010). Cancer cells use the same genetic programs, mediated 
by the same transcription factors, as healthy cells do, which become activated at the wrong time 
(Leber & Efferth, 2009). Also, with aging, the stroma/cell microenvironment changes 
progressively, accumulating enough damage to cause epithelial cells deregulations even in the 
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absence of genetic damage. In breast, the myriad of genetic changes cause tumour 
development, often remaining as ductal carcinoma in situ. Cells become invasive when gain the 
capacity to compromise the integrity of the basement membrane or the myoepithelial layer, 
allowing the luminal cells to contact with the stromal ECM components, such as collagen type-I. 
This new environmental signals lead to aberrant polarity, up-regulation of MMPs, invasion and 
metastasis (Bissell et al., 2011) (Figure 6).        
 
 
Figure 6:  Normal mammary microenvironment to breast tumour microenvironment. The normal 
tissue microenvironment acts as a barrier to tumourigenesis in normal tissue homeostasis 
conditions, exerting suppressive forces to prevent tumourigenesis (bottom left in graph). But the 
microenvironment can also be permissive to tumour growth. The combination of mutagens, 
inflammation, growth factors and other tissue-associated promotional forces can breach the 
barrier, allowing tumour formation which may result in cancer development (top right). Adapted 
from Bissell et al., 2011. 
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2.3. Invasive breast cancer through ECM remodelling  
 
Human mammary epithelial cells in vivo express several integrins; however they are altered 
in the majority of human breast carcinomas, suggesting that deregulation of integrin expression 
may be an important parameter in breast tumourigenesis. A study reveals that deregulation of 
integrins in MDA-MB-435 is more severe in metastatic cells, suggesting a correlation between 
deregulation of integrin expression and aggressive tumour behaviour (Howlett et al., 1995). 
To cross the basement membrane, tumour cells itself changes proprieties like increasing 
matrix degrading enzymes (MMP), altering cell adhesion (integrins), fluctuating receptor-
facilitated laminins assembly and laminins endocytosis (example: loss of laminins-111), and 
ECM signalling mechanisms. Basement membrane also suffers remodelling, allowing invasive 
sites (Muschler & Streuli, 2010). MMPs degrade the basement membrane, cell-cell and cell-
matrix adhesion, and activate growth factors and inactivated MMPs. (Gangadhara et al., 2012). 
Microenvironment has a huge role to drive cancer progression. Normal myoepithelial cells have 
the opposite function, they secrete inhibitors of ECM-degrading proteases, for instant, in the 
breast cancer case, maspin (Muschler & Streuli, 2010). Maspin can inhibit integrin subunits α2, 
α4 (can promote indirectly MMP-2 production), α6 and αv (inhibiting malignant capacity) but 
controversy induce integrin subunit α5 (Koistinen & Heino, 2000). 
After crossed the basement membrane, tumour cells are exposed to a different matrix, 
proteases and cytokines; leading to the increase secretion of matrix components, such collagen 
and hyaluronan and increase lysyl oxidase activity. All this imparts distinct biochemical and 
mechanical influences, which can foster malignancy and metastasis (Muschler & Streuli, 2010). 
To acquire an invasion phenotype, cells suffer changes like loss of cadherin-dependent 
intercellular adhesion, epithelial-mesenchymal transition, and a partial degradation and 
remodelling of the ECM. Integrins binding to ECM components is implicated in cell growth, 
survival, adhesion, migration, invasion and tumour metastasis. In ductal carcinoma, an increase 
in MMP-2 and MMP-9 expression had been noted, similarly, in the stroma around pre-invasive 
lesions in MMP-1, -2, -3, -9 and -11. At genetic level, MMP-1, -11 -12 and -13 genes are up-
regulated and related with poor prognosis (Gangadhara et al., 2012). 
 
2.4. The association between cell adhesion and the invasive phenotype - cadherins 
and integrins 
 
In humans, the cellular response to molecular messengers synthesized and released by 
neighbour cells is critical to regulate cell growth, survival and differentiation. Adhesion receptors 
link cells to their surroundings, either other cells or the ECM, and, concomitantly, mediate 
information flow into the cells by activating the same signaling pathways as do growth factor 
receptors (Ivaska & Heino, 2011).  Epithelial cells connect to their neighbourhood through 
diverse intercellular adhesion complexes which include adherent junctions (anchored to cortical 
actin and microtubules), tight junctions and desmosomes. Also, cells attach to the underlying 
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basement membrane through other adhesion complexes, namely focal adhesions (FAs, 
connection to the basement membrane) and hesmidesmosomes. Adhesion events are mainly 
mediated by cadherins and integrins which are transmembrane glycoproteins that play an 
important role in the physiological balance of epithelial cells (Epifano & Perez-moreno, 2012). 
Cancer cells typically develop alterations, indeed, expression of genes encoding cell-to-cell and 
cell-to-ECM adhesion molecules is altered in some aggressive carcinomas (Hanahan & 
Weinberg, 2011). 
Adhesion receptors cooperate to coordinate response to the signals derived from other cells 
and from the microenvironment. This crosstalk response allows cells to rapidly respond to 
biochemical or mechanical inputs that are transformed in intracellular signals regulating cell 
behaviour (Figure 7). De-regulations in this coordination may result in chronic activation of the 
stroma (such as secretion of soluble factors, cytokines, chemokines, MMPs and changes in 
ECM composition). When this occurs, the signaling loops of cells may become permanently 
activated with gain of migratory and invasive capacities.   
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Figure 7: Coordinated regulation of FAs and AJs in epithelial cells is involved in the crosstalk of 
epithelial cells between themselves and with the stroma. FAs and AJs share downstream 
signaling molecules, including Rho GTPases and Src, and interactions with actomyosin 
cytoskeleton, which contribute to the coordination of their adhesive network. During 
tumourigenesis coordination crosstalk between FAs and AJs in epithelial cells is impaired, and 
may result in the chronic activation of the stroma (e.g., secretion of soluble factors, cytokines, 
chemokines, MMPs and changes in ECM composition). These can generate perpetuating 
signaling loops without a clear endpoint that, if unresolved, may lead to further epithelial 
transformation with gain of migratory and invasive characteristics (Epifano and Perez-Moreno 
2012). 
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2.5. Alterations in interactions and mechanisms during breast cancer progression: 
integrins and cancer 
 
The normal mammary microenvironment is capable of reverse the malignant phenotype of 
breast cancer cells, suggesting that cancer cells need an abnormal microenvironment to 
progress (Polyak & Kalluri, 2010). Tumour microenvironment is increasingly recognized as a 
major regulator of carcinogenesis (Place, et al. 2011). 
 
The integrin family are transmembrane glycoprotein receptors that mediate cell-cell and cell-
matrix adhesion, forming focal adhesions that contact with ECM ligands by the long extracellular 
domain (i.e. fibronectin, laminin, vitronectin and collagen). Integrins are the major receptors for 
the environment of the cell (Pontier & Muller, 2009). Integrins recognize some specific 
sequences like RGD and related sequences, found in ECM. Disintregins (originally found in 
viper venoms) block integrins’ functions. They are composed by RGD sequences and act as an 
inhibitor of platelet aggregation (required component of metastasis) and adhesion. In addition, 
integrins regulate not only adhesion, but also cell proliferation, differentiation, survival and gene 
expression. Integrins have a role during various cancer stages such as malignant 
transformation, tumour growth and progression, invasion and metastasis and apoptosis 
(Mizejewski, 1999). 
Integrins which are composed by heterodimers of one of 18 α-chains and one of 8 β-chains, 
accounting at least 24 combinations, where 12 contain integrin subunit β1 (Koistinen & Heino, 
2000). Those combinations have specific tissue distribution and specific and non-redundant 
functions as shown by their specificity for ECM ligands (Lahlou & Muller, 2011). Integrins have a 
large extracellular domain (N-terminal), a transmembrane domain, and an intercellular domain 
(C-terminal). Integrin subunit α1 is the smaller intracellular domain (less that 40 amino acids) 
and integrin subunit β4 the bigger one (1018 amino acids) (Koistinen & Heino, 2000). 
The whole Integrin subunit α has 150-200 kDa, is composed by a heavy and light chain with 
disulphide bond and seven N-terminal (60 amino acids) forming b-propeller. This structure, with 
β-chain, is the ligand binding domain and it is need to stabilize the active conformation of 
integrin receptor. The α-chains exhibit four repeat amino acid segments believed to bind 
calcium (Ca
2+
) and possibly other divalent cations such as Mg
2+
 and Mn
2+
. These Ca
2+ 
binding 
regions associated with amino acids 100–200 on the β-chain (bI-like domain) form the ligand 
binding site, a cation-dependent process. The N-terminal half of the integrin α-chain is folded 
into a β-sheet propeller motif that contains seven weak amino acid sequence repeats 
(Mizejewski, 1999). 
The β-subunits have 90-110 kDa (except β4 with 210 kDa) (Koistinen & Heino, 2000)  and 
exhibit at least four cysteine-rich repeats (C-terminal), in linear juxtaposition, that stabilize the 
large extracellular amino terminal loop (Mizejewski, 1999). 
The secondary structure is thought to be arranged in a geometric configuration around a 
central axis with Mg
2+
 ions bound to the upper faces of the propeller and Ca
2+
 ions bound to the 
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lower faces. The intracellular domains of both the α- and β-chains are short (except β4) following 
their transmembrane insertion. The short β-cytoplasmic tails is capable of binding to 
cytoskeleton-associated proteins that link the integrins to the actin cytoskeleton system, through 
actin, vinculin, talin and paxillin. A calreticulin association is known with α-chains that regulate 
the calcium transmembrane channel influx (Mizejewski, 1999). 
  
2.6. Integrins patterns 
 
Integrins, when over-expressed in tumour cells, contribute to cancer progression and 
metastasis by increasing cell migration, invasion, proliferation, survival and tumour 
angiogenesis, through an intracellular and extracellular signalling involving crosstalk between 
RTK or G-protein-coupled receptor and integrins; but also involving integrin endocytosis and 
recycling (Lahlou & Muller, 2011). The effects of ECM on cells are mainly mediated by integrins 
by transmitting mechanical and chemical signals. Changes in adhesion signalling and integrins 
patterns are crucial to invasion process (Guo & Giancotti, 2004). 
The binding of integrins and ligands are controlled by a mechanism that need a receptor 
clustering alone, or ligand occupancy plus receptor clustering, or clustering, ligand occupancy, 
and tyrine kinase activation. This process also needs an outside-in signalling (bidirectional 
signalling) and conformational changes in the chains, leading to an affinity modulation for the 
ligand. Moreover, adhesion plaques are formed at the cell membrane that serve as focal points 
for recruitment of proteins (talin, veniculin, paxillin, etc.) to provide cascade interfaces for actin, 
G-proteins, calcium-binding proteins, MAP and tyrosine kinases (Src family) and transcription 
factors, such NF-ĸB (Mizejewski, 1999). 
Integrins are involved in all stages of metastasis: migratory behaviour, invasion and 
colonization of target tissues. To be able to migrate, metastatic cells need to have the ability to 
generate locomotors forces, capacity to breach vessel walls, ability to navigate through the 
dense collagen tissue surrounding tumours, ability to degrade the extracellular matrix (ECM) 
and squeeze through the interstitial spaces, described as amoeboid type, colonize foreign 
microenvironments, and dynamic interaction with changing microenvironment. For those 
reasons, integrin-mediated adhesion had a critical role in metastasis process. Integrins interact 
with ECM components, like collagen and laminin, for structural and functional integrity, but also 
promote growth factor receptors, leading to the activation of downstream signalling pathways, 
such cell cycle progression and oncogenic transformation (White & Muller, 2007). 
Malignant transformation is characterized by disruption of cytoskeleton organization, 
decreased adhesion (by alteration in cell adhesion receptors) and altered adhesion-dependent 
responses. Studies reveal that different tumours have different patterns of integrins type and 
distribution (Table 1). Reduced levels of integrin subunit α5, α3, and α2 expression have been 
reported in carcinomas, whereas increased levels of α6β4 appear in head, neck, and skin 
tumours. Both quantitative and qualitative alterations in integrin cell surface patterns have been 
observed in vitro and in vivo. In turn, this altered integrin expression may have a role in invasion 
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and metastasis process. For instant, α5β1 is correlated with low levels of transformation in 
certain tumours (i.e. ovary cancer cells) and αvβ3 is associated with high transformation. In 
human malignant mammary tumour progression, α3β1 is present in non-neoplastic and 
fibroadenomas but were low or absent in invasive mammary carcinomas. Also, α2β1 is high 
express in normal breast tissue (Mizejewski, 1999) (to maintain the differentiation of cell 
phenotype) and low α2β1 level is found in breast adenocarcinoma (in collagen type-I, it promote 
MMP-1 by PKC-z and nuclear factor κ-light-chain-enhancer of activated B cells (NF-κB) 
pathways, and MMP-13 by activation of p38) (Koistinen & Heino, 2000), like low level of α5β1 
and αvβ3. In contrast, α6β4 is up-regulated in breast tumour, and it is an indicator of poor 
prognosis and metastatic potential. In breast cancer, α6β4 is reduced in primary site and 
constant level at metastatic sites (Mizejewski, 1999). 
The luminal epithelial cells of the human breast express the laminin and/or collagen integrin 
receptors: α1β1 (mainly in collagen type-IV), α2β1, α3β1, αvβ1, α6β1 and α6β4 (mainly in laminin) 
(Weaver et al., 1996), although the fibronectin express also α5β1 and α4β1  (Koistinen & Heino, 
2000). α2β1 and α3β1 have a basolateral expression, while α6 and β4 are present where cells 
interact with the basement membrane at the basal surface. A study reveals that high integrin 
subunit α6 level is correlated with decreased patient survival, more aggressive tumour 
phenotype (Weaver et al., 1996) and increase migratory potential (Koistinen & Heino, 2000); 
moreover a dominant-negative integrin subunit β4 is correlated with decreased metastatic 
potential. Until now, there are no studies revealing the importance of alterations in the adherens 
junction cell–cell adhesion system and relation to alterations in cell–ECM or trophic factors 
(Weaver et al., 1996) (Table 1). 
 
Table 1: Integrins in cancer progression (Cheresh & Desgrosellier, 2010) 
 
 
 
 
 
 
24 
 
2.7. Integrins signalling in breast cancer progression 
  
2.7.1. PI3K pathway 
 
Integrin, localize in the tips of the forward reaching invasive structures, suggesting a traction, 
locomotion and migration role. Integrins clustering at focal adhesion sites allows regulation of 
actin polymeration and cytoskeleton rearrangement, mediated by Rho family including Rho, Rac 
and Cell division control protein 42 homolog (Cdc42) (White & Muller, 2007). Furthermore, 
Cdc42 and Rac1 could be the link between PI3K and integrin, like α3β1 that are involved in cell 
migration/invasion in breast cancer by regulating MMP-2 production. α3β1 also have correlation 
with metastatic capacity by increasing MMP-9 activity (Koistinen & Heino, 2000) (Figure 8). 
Epidermal growth factor (EGF) receptors interact with β1-itegrins, resulting in an increase auto-
phosphorylation of EGF and consequent activation of pathways. The migratory and invasive 
proprieties depend on local gradients of chemotactic growth factors such HGF and EGF (White 
& Muller, 2007) (Figures 8 and 9). 
 
 
Figure 8: Integrin-receptor-tyrosine-kinase signalling induces cell migration and invasion (Guo 
& Giancotti, 2004) 
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Figure 9: Integrin pathways leading to tumour progression 
 
2.7.2. EGFR and ERBB-2 pathway 
 
Moreover, epidermal growth factor receptor (EGFR), as well as ERBB-2, up-regulates 
integrin subunit β1 function and breast cancer progression, via PI3K. ERBB-2 also down-
regulate integrin subunit α6 and may contribute to fibronectin-depend invasion (Koistinen & 
Heino, 2000). A study reveals that α6β4 cooperates with EGFR and ERBB2, amplifying genes 
encoding RTK, and consequently promoting carcinoma growth (Guo & Giancotti, 2004) (Figure 
9).  
 
2.7.3. FAK pathway 
 
The activation of focal adhesion kinase (FAK) requires both ligand binding to integrins 
(integrin subunits β1 β2 and β3) and intact cytoskeleton (binding to paxillin, talin and maybe to 
vinculin). These binding leads to FAK auto-phosphorylation, in turn it is a binding site for kinases 
like Csk, Fyn and Src; consequently it may induce MAPK/ERK/JNK pathway to promote MMPs 
production (Koistinen & Heino, 2000) (Figure 10). 
The switch of type and frequency of integrins is dependent of microenvironment. ECM 
remodelling involves alteration in integrins expression, which regulates FAK/Src family kinase 
activation and the cross-talk with soluble growth factor receptors and cytokines. FAK activation 
is present in invasive breast cancer, so Src family members could be a target to suppress 
tumour cell migration (Gangadhara et al., 2012). Integrin subunit β1 blocking attenuates EGF 
signalling and cell cycle progression. Also, blocking integrin subunits β1 or β4, or FAK or Src, 
impair tumourigenesis. For example, blocking α5β1 and αvβ3 receptors impair the growth and 
26 
 
metastasis of invasive human breast cancer (White & Muller, 2007) by inhibition of MMP-9 and 
cell adhesion. αvβ3 and αvβ5 are involved in bone cancer, in metastatic potential and migration; 
and cell adhesion, invasion and proliferation, respectively (Koistinen & Heino, 2000). A study 
reveal that tumour expressing αvβ3, normally not found in normal mammary tissue, also have 
up-regulated MMPs (White & Muller, 2007). αvβ3 can associate with uPAR, inducing the 
conversion of plasminogen in plasmin, that can degrade ECM components, directly or indirectly 
by activation of MMPs (Guo & Giancotti, 2004). Integrin expression is also associated with 
invasion process, by MMPs. A good therapeutic strategy could be inhibition of integrin, to 
reduce MMP activation and consequently reduce invasion behaviour (White & Muller, 2007). 
 
 
Figure 10: Integrin signalling (Guo & Giancotti, 2004) 
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2.7.4. Integrins, MMPs and mechanisms 
 
One study reveals that β4-shRNA decreases integrin subunit α6, concluding that α6β4 
increase tumour survival and decrease apoptosis (via vascular endothelial growth factor 
expression – VEGF) and p53-dependet caspase-3 (Lipscomb et al., 2005). These 
transformations involve increase phosphorylation and glycosylation of integrins, and decreased 
affinity. However, it is important to remain in mind that, although all this alteration, some 
integrins still maintain their normal expression during malignant transformation, tumour 
progression and metastasis (Mizejewski, 1999). αvβ3 co-localized with MMP-2 in melanoma cells 
that facilitate tumour cell invasion. αvβ3 not only induce MMP-2 but also promotes inhibition of 
inhibitor of MMP-2. Integrin subunit β1 and α6β4 also promote MMP-2 production (Koistinen & 
Heino, 2000). Others examples are: α4β1 that initiates the growth and spread; α5β1 and αvβ3 that 
are expressed in advanced tumour and metastases, suggesting that integrins may have 
prognostic value; increased α4β1 together with decreased α6β1 that is correlated with 
metastases; αvβ3 and αvβ5 that are implicated in neo-vascularisation; α6β4 that induces p21 
cyclin-dependent kinases (Mizejewski, 1999) and apoptosis via p53 (inhibiting malignant 
capacity). However, if p53 is mutated (inactive form), α6β4 facilitate cancer progression and 
invasion through PI3Ks (Koistinen & Heino, 2000). Anoikis is a process in which normal cells 
died by apoptosis after matrix detachment (Mizejewski, 1999). However, cancer cells are 
relatively resistant to anoikis (Guo & Giancotti, 2004). Anoikis can be distinguished from 
necrosis by cell/nuclear morphology, inter-nucleosomal DNA cleavage, nuclear lamina cleavage 
and loss of Bcl-2. α5β1 prevent apoptosis of cells attached to fibronectin by activating the Bcl-2 
pathway (anti-apoptotic)  (Mizejewski, 1999). Also α5β1 induces MMP expression by binding to 
PEA3- and activator protein-1 (AP-1) sites of MMP promoter (Koistinen & Heino, 2000). p63 
confer resistance to anoikis through integrin subunit β4. Also NF-κB confer resistance to 
apoptosis through integrin subunit β4 (Pontier & Muller, 2009). 
Anti- Tumour necrosis factor-α (TNF-α) inhibit α5β1 and MMP-9, but not MMP-2. It is possible 
that this inhibition take place by Raf-1 and mitogen-activated protein kinases pathway or 
Ras/MAP kinases. Also NF-ĸB, Specificity Protein-1, and AP-1 may be involved at least in TNF-
α-related induction of MMP-9 expression; due to the fact that in breast cancer cells over-
express Bcl-2, increase NF-ĸB-dependent transcriptional MMP-9 activity, TIMP-1 and TIMP-2 
(Koistinen & Heino, 2000). 
 
2.8. Integrins, cadherins and ROS 
 
Adhesions have two major roles in migration: traction and signalling. Focal adhesion is a 
cluster of integrin receptors, associated with complexes of signalling and proteins linked to 
cytoskeleton, giving structural and signalling functions. During migration, nascent adhesions are 
formed at the leading edge and integrin-mediated adhesions are dissembled at rear-end, 
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allowing cellular movement. This turnover of focal adhesions is regulated by FAK and Src 
(Huttenlocher & Horwitz, 2011). 
Integrins are the major cell-(ECM adhesion receptors and cadherins are cell-cell adhesion 
receptors. For that reason, it is though that there is a molecular crosstalk between them. Small 
GTPases of the Ras and Rho family, Src, FAK and phosphatidylinositol 3’-kinase (PI3K) are 
some example of this crosstalk. Another example is Rap1 that acts as a turnabout for 
endosome signalling and membrane traffic to delivery integrins and cadherins. It was suggest 
that ROS (like free radicals and peroxides –superoxide anion and hydrogen peroxide–) also 
play a role in the modulation of this crosstalk. Activation of redox signalling at integrin-mediated 
cell-matrix adhesion sites induces assembly of focal adhesions, but also, in turn, integrins 
induce ROS burst by promoting changes in mitochondrial metabolic/redox function. Contrary, 
activation of redox signalling at cadherin-mediated cell-cell junctions induces disassembly of 
adherent junctions. ROS are involved in the redox-dependent regulation of multiple signal 
transduction pathways, including cell adhesion, migration, proliferation, differentiation, and 
survival. However, ROS at high levels (production of ROS is higher that cellular antioxidant 
mechanisms), cause cellular damage through oxidative stress. Caveolae/lipid rafts, focal 
adhesions and cell-cell contacts promote NADPH oxidases, allowing ROS production and 
activation of specific redox signalling events (Goitre et al., 2012). 
 
2.9. Tumour microenvironment and integrins in lung cancer 
 
The interactions of cancer cells with components of their tumour microenvironment are bi-
directional and are crucial for cancer progression. When associated with cancers, mesenchymal 
stromal cells are often called carcinoma-associated fibroblasts (CAFs) and 
monocytes/macrophages are referred to as tumour-associated macrophages (TAM). CAFs 
display a greater ability than normal fibroblasts to enhance the tumourigenicity in non-small-cell 
lung cancer (NSCLC), over-expressing genes involved in TGF-β signaling, focal adhesion, and 
the MAPK signaling pathway (Saintigny & Burger, 2012). Up-regulated genes in TAMs (EGF, 
COX-2, MMP-9, uPA, VEGF, HGF) contributed to suitable microenvironments for lung cancer 
invasion and metastasis. The increase of invasiveness was also correlated MMP-9. Anti-uPA 
and anti-MMP-9, but not anti-VEGF monoclonal antibodies, can inhibit TAM-induced invasion 
(R. Wang et al., 2011). 
 Lung epithelial cells adhere to a basement membrane, rich in laminin-332, where the main 
integrin receptors are α6β4 and α3β1. Silencing α5β1 integrin, the major fibronectin receptor, 
impairs the mitogenic effect of nicotine on lung cancer cells. Increase α5β1 level is correlated 
with lymph node metastasis in NSCLCs. αvβ6 integrin is also a negative prognostic factor for the 
survival of NSCLC patients. αvβ6, similarly to α5β1, enhances ability to adhere, migrate, and 
invade the fibronectin-rich matrix that surrounds NSCLCs, through activation TGFβ signaling 
(Caccavari et al., 2009). 
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There are different tumour environment therapies approaches in NSCLC. Target hypoxic 
cells in lung cancer is one approach (example: tirapazamine), but hypoxia decreases therapy 
response. Another approach is to alter microenvironment (and consequently some factors like 
VEGF and HIF-α) of NSCLC to impair hypoxia. EGFR is over-expresses in 80% of NSCLC. 
EGFR activation leads to the activation of multiple intracellular signaling pathway including the 
Ras and Akt pathways. And the PI3K pathway plays a key role in controlling cell proliferation, 
growth and survival, is activated in many cancers. For that reason, inhibitors of the 
EGFR/PI3K/Akt pathway (example: monoclonal antibody cetuximab, or small molecule tyrosine 
kinase inhibitors gefitinib  and erlotinib) is another approach that  “normalize” tumour vessels, 
allowing for increased chemotherapy delivery or improved oxygenation and radiosensitivity 
(Graves, Maity, & Le, 2010). 
 
2.10. Tumour microenvironment therapies 
 
Currently, there are different approaches to tumour microenvironment therapies: aromatase 
inhibitors, angiogenesis-modulating agents, inhibitors of HER family receptors, VEGF inhibitors, 
MMP inhibitors, antibodies targeting FAP, c-Met antagonists and multi-targeted RTK inhibitors, 
bisphosphonates, denosumab and microenvironmental reprogramming. This last hypothesis is 
an over-expression of histidine-rich glycoprotein that induces normalization of TAMs (which 
convert M2 pro-tumour phenotype to M1 anti-tumour phenotype) and blood vessel structure; 
and consequently decreases tumour growth and increases sensitivity to chemotherapy. All the 
therapies are based on chemotherapy, metronomic therapy (low doses of chemotherapy with 
low side effects) or epigenetic therapy  (Place, et al. 2011). 
Four classes of integrin inhibitors are currently in preclinical and clinical development: 
monoclonal antibodies (example: Vitaxin/Abegrin; MedImmune, Gaithersburg, MD), synthetic 
peptides containing an RGD sequence (example: Cilengitide; Merck KGaA, Darmstadt, 
Germany), non-RGD antagonists (such as ATN-161, inhibitor of integrin α5β1), and general 
integrin-targeted therapeutics (Danhier, Le Breton, & Préat, 2012). 
Vitaxin is an humanized monoclonal antibody to the integrin αvβ3., that after clinical trial 
phase I concluded that it is well tolerated with little or no toxicity (Gutheil et al., 2000). However, 
the absence of objective disease responses seen in clinical trial II was attributed to limitations of 
affinity and stability in vivo.  After affinity improvement, Abegrin appears and follows clinical trial 
I and II, unfortunately, treatment alone or in combination did not significantly impact overall 
survival. c7E3 (abcixmab) is approved by the U.S. Food and Drug Administration and 
recognizes αvβ3 and αIIbβ3. It has an anti-angiogenic and antitumour activities, but also anti-
metastatic activity by preventing the adhesion (Millard et al., 2011). 
Cilengitide, RGD antagonist, is currently in clinical phase III for treatment of glioblastomas 
and in phase II for several other tumours. This drug is anti-angiogenic and inhibits integrins 
αvβ3, αvβ5 and α5β1 (Mas-moruno, Rechenmacher, & Kessler, 2010). 
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ATN-161 has antiangiogenic effects by inhibition of α5β1. ATN-161 inhibited VEGF-induced 
migration and capillary tube formation in vitro and in vivo (Wang et al., 2011). Another inhibitor 
of α5β1 is volociximab. Clinical trial phase I showed that 8 patients have partial response and 17 
had stable disease; concluding that volociximab combined with carboplatin and paclitaxel was 
generally well-tolerated and showed preliminary evidence of efficacy in advanced NSCLC 
(Besse et al., 2013). Additional Phase II and III trials involving volociximab as a are currently 
underway for the treatment of metastatic melanoma, non-small cell lung cancer and peritoneal 
cancer (Millard et al., 2011). 
Nowadays, there are three U.S. Food and Drug Administration approved therapeutics 
targeting αIIbβ3 (abciximab, eptifibatide and tirofiban) and one α4 antagonist (natalizumab) 
(Millard et al., 2011) (Table 2). 
 
Table 2: Integrin inhibitors (Chen, Alexander, & Wayne, 2012) 
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3. Breast and lung cancer 
 
3.1. Cancer incidence 
 
Breast and lung cancer incidence is increasing in women, with an estimated 232,340 and 
110,110 new cases; and estimated 39,620 and 71,220 deaths worldwide, respectively, making it 
both the most commons types of cancer affecting women (Figure 11) (American Cancer 
Society, 2013). It is also known that 10% of women with breast cancer develop a second, and 
women with breast cancer have a 3- to 7-fold increased relative risk of cancer developing in the 
opposite breast (Richie & Swanson, 2003). 
 
 
Figure 11: Estimated new cancer cases and deaths worldwide for leading cancer sites 
(American Cancer Society, 2013) 
 
Some studies reveal that 95% of breast cancers are carcinomas, meaning that they arise 
from breast epithelial elements. There are two groups: in situ carcinomas (arise in ductal or 
lobular epithelium) and invasive or infiltrating carcinomas (potential for metastases)  (Richie & 
Swanson, 2003). Invasive ductal carcinoma is the most common morphological subtype, 
representing  80% of the invasive breast cancers (Sandhu et al., 2010).  
 
3.2. P-cadherin in breast cancer 
 
3.2.1. Molecular characterization  
  
The cadherin superfamily is composed by classical cadherins (main components of cell-cell 
adhesion), by non-classical cadherin (like desmosomal cadherins) and by proto-cadherins 
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(implicated in neuronal plasticity) (Paredes et al., 2012). Classical cadherins are calcium-
dependent cell-cell adhesion proteins, localized in adhesion-type junctions (Paredes et al., 
2007),  including CDH1/E-cadherin (epithelial), CDH2/N-cadherin (neuronal), CDH3/P-cadherin 
(placental) and CDH4/R-cadherin (retinal) (Albergaria et al., 2011). 
As all classical cadherins, P-cadherin is a transmembranar glycoprotein with 118 kDa 
(Figure 12). These classical cadherins promote mainly homotypic interactions between 
cadherins of the same type, forming homodimers (Paredes et al., 2007, 2012). 
The extracellular domain is composed by five cadherin repeats (EC), which are sequences 
of 110 residues, designated EC1-EC5. The EC1 is the most important for the adhesion role. The 
normal conformation of P-cadherin is only stable in the presence of calcium which is required to 
the cell-cell adhesion function. Calcium-binding sites are conserved sequences and are located 
between neighbouring EC repeats (Paredes et al., 2012). The extracellular domain creates 
lateral dimmers (Albergaria et al., 2011) by the amino-terminal domain, a zipper-like structure 
between neighbour cells (Figure 12) (Paredes et al., 2007). 
 
 
Figure 12: Schematic representation of the structural components of the P-cadherin adhesive 
junction (Albergaria et al., 2011). 
 
For an entire review: Paredes et al., 2005, 2007, 2012 and Albergaria et al., 2011. 
 
3.2.2. P-cadherin over-expression 
 
Cadherins affect tumourigenesis and tumour behaviour for the reason of their role in invasion 
and migration. P-cadherin is frequently found in breast, gastric, endometrial, colorectal and 
pancreatic carcinomas (Albergaria et al., 2011). With the development of new antibodies, 30% 
to 50% of invasive ductal carcinoma were identify P-cadherin positive, but not in lobular type 
(Paredes et al., 2007). In other studies, P-cadherin was described in 20% to 40% of invasive 
breast carcinoma and in 25% of ductal carcinoma in situ (Albergaria et al., 2011). 
Several hypotheses appear to try to explain the aberrant presence of P-cadherin in breast 
cancer. One theory is that P-cadherin should be involved in the proliferative process; however 
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the presence of this protein did not change the proliferative rate, indicating that P-cadherin is 
not directly involved in cell cycle (Paredes et al., 2007). Although others studies reveal the 
opposite (Paredes et al., 2012). Another theory is that P-cadherin should be an oncofetal 
protein member, based on the fact that P-cadherin is highly expressed in embryogenesis and 
neoplasias but weakly expressed in adult tissues; however there is no confirmation of this 
hypothesis. A third theory is that P-cadherin expression could be related to a histogenetic origin 
in cap cells, due to the fact that caps cells have a high migration capacity without oestrogen 
receptors and with the ability to differentiate into myoepithelial cells, suggesting that they could 
be responsible for the development of P-cadherin positive breast cancer cells. Another idea is 
that P-cadherin is mis-expressed, following epithelial transformation; this lead to the alteration of 
the behaviour of the tumour cells and consequently contribute to the poor survival of women 
with P-cadherin positive breast cancers (Paredes et al., 2007). 
 
P-cadherin expression is correlated with high histological grade tumour, lack of oestrogen 
and progesterone receptors, increased aggressiveness (Knudsen & Wheelock, 2005), Bcl-2 low 
expression, short-term overall and disease-specific survival, short-term relapse-free survival, 
increased motility (Albergaria et al., 2011), nuclear pleomorphism and decreased cell polarity 
(Paredes et al., 2007). In addition, P-cadherin is positively associated with Nottingham 
prognostic index, p53, Her2, lymph node stage, antigen Ki-67 (associated with cell proliferation), 
recurrence, distant metastasis, invasion (Liu et al., 2012), high proliferative rate (MIB-1 gene), 
high mitotic index and decreased cell differentiation (Paredes et al., 2007). For all these 
reasons, P-cadherin is considered a marker of poor prognosis (Albergaria et al., 2011).  
P-cadherin is also a basal-like marker (Figure 13) like cytokeratins (CK5/6, CK14, CK17), 
vimentin, αB-crystalline, caveolins 1/2 and EGFR (Albergaria et al., 2011). 
 
 
Figure 13: Expression of P-cadherin in all molecular subtypes of breast cancer, mainly in basal-
like type (Liu et al., 2012) 
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3.2.3. P-cadherin and invasion of breast cancer cells 
 
Local invasion and distant metastasis are the later stage of carcinomas progress. Those 
processes depend on the cell-cell and cell-matrix interactions. The disruption of these 
adhesions leads to motility, invasion and metastasis of tumour cells (Albergaria et al., 2011). 
The role of P-cadherin in the carcinogenic process is still controversial, since it depends on 
cancer cell model studied. For instance, P-cadherin acts like a tumour suppressor gene in 
malignant melanoma, in which there is a gradual loss of P-cadherin, allowing cells to invade and 
migrate. In colorectal cancer cell line and melanomas, it is suggest that P-cadherin have an anti-
invasion and pro-adhesion role. However, in breast cancer, P-cadherin expression increase and 
enhance cell invasion and tumour aggressiveness (Paredes et al., 2007). CDH3 gene acts as 
an oncogene and consequently P-cadherin increased tumour cell motility, directional cell 
migration and invasiveness (Albergaria et al., 2011). 
Some studies reveal that the lost of E-cadherin leads to an up-regulation of N- and P-
cadherin, a process known by cadherin switching. This switch is, in part, responsible for the 
tumour cell invasion, metastasis and, in some cases, the promotion of epithelial-to-
mesenchymal transition. The cadherin switch from E- to P-cadherin is common during embryo 
development and some reports describe it during tumour progression. Indeed, some breast 
cancer models maintain the E-cadherin expression and the abnormal P-cadherin expression. 
Although, it is though that P-cadherin only is functional when the cell system already express an 
endogenous and functional cadherin, like E-cadherin in breast cancer. This suggest that P-
cadherin interact with E-cadherin and promote the disruption between E-cadherin and β-/p120-
catenin, a negative signal to tumour cell growth and invasion (Albergaria et al., 2011). 
Besides the role of cadherin in cell polarity, cadherin are important to cell-cell adhesion. In 
breast cancer, cadherin level is normally altered. For instance P-cadherin over-expressing, in an 
E-cadherin wild-type model, is correlated with poor survival and high aggressiveness. P-
cadherin promote invasion and migration, by increasing of MMP-1/-2, which in turn cleave P-
cadherin (soluble P-cadherin) and increase invasion (Ribeiro et al., 2010). 
In addition, P-cadherin also regulate an overall genetic program of breast cancer cells, like 
genes involved in signal transduction, in growth factors (VEGF-C) and Fibroblast growth factor 
receptor 4 (FGFR4), in cell cycle [Cyclin-A2 (CCNA2)], in metalloproteinases (MMP-1/-2), in 
cytokines and inflammation [Interleukin-24 (IL-24)] (Albergaria et al., 2011).  
 
3.2.4. P-cadherin as a potential therapeutic target 
 
P-cadherin plays a role in the cancer cell survival, invasiveness and metastatic potential. For 
that reason, CDH3/P-cadherin is a possible target for immunotherapy of breast cancer, as a 
novel tumour-associated antigen, meaning that was strongly expressed in tumour cells but not 
in normal cells. P-cadherin silencing in breast cancer cells in nude mouse inhibit in vivo tumour 
growth. Recently, a monoclonal antibody anti-P-cadherin PF-03732010 shows an anti-tumour 
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and anti-metastatic activity in different cancer models with no side effects in mice. It also shows 
no affinity to other cadherins, decreased Ki-67, increased caspase-3 expression (Albergaria et 
al., 2011), and suppressed β-catenin, Cyclin D1, vimentin, Bcl-2 and survivin expression 
(Paredes et al., 2012). The next step should be developing a reproducible method to quantify P-
cadherin in human tumours (Albergaria et al., 2011). 
P-cadherin over-expression occurs in about 30% of all breast carcinomas, leading to 
invasion and migration. Three breast cancer cell lines (MCF7.AZ/Mock, MCF7.AZ/Mock and 
SUM149) were treated with azurin to evaluate P-cadherin level. This study concluded that P-
cadherin protein level decreases 30-50% in MCF-7/AZ.Pcad and SUM149, but the levels of E-
cadherin remain unaltered. Azurin is able to decrease P-cadherin level (protein level and not 
mRNA level) leading to a tumour less aggressive. Also, azurin decrease invasion and MMP-2 
activity; and decrease the phosphorylation levels of both FAK and Src proteins. Azurin could 
possibly be considered a therapeutic tool to treat over-expressing P-cadherin in a wild type E-
cadherin context, via FAK/Src signaling (Bernardes et al., 2013). 
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4. Objectives and thesis outline 
 
P-cadherin over-expression in breast cancer is correlated with poor prognosis (Paredes et 
al., 2012). As previously showed, azurin, a bacterial protein, decreases P-cadherin protein level 
(an adhesion protein) in an E-cadherin wild type model of breast cancer. For that reason, azurin 
is a potential breast cancer drug and P-cadherin is a potential therapeutic target. Also, azurin 
decreases the phosphorylation level of FAK and Src (Bernardes et al., 2013), a down-stream 
signalling of integrins that lead to migration and invasion. 
Lung cancer, in particularly NSCLC, has similar signalling involved in adhesion as in breast 
cancer. To try to prove a general impact of azurin in cancer, we will use both models. 
Previously, our group has performed a microarray analysis of MCF7/AZ.Pcad cell line 
treated with azurin (100µM) during 48h. The results were then analysed using the DAVID 
(Database for Annotation, Visualization and Integrated Discovery) and software One of main 
categories enriched in genes with decreased expression in treated cells compared to normal 
cells was biological adhesion, accounting for the biological processes of cell-to-cell and cell-to-
matrix adhesion. To confirm this information, a functional validation was done in three P-
cadherin over-expressing breast cancer cell lines: MCF7/AZ.Pcad, SUM149 and BT-20 and also 
in one lung cancer cell line A549, to confirm if this was one possible mode of action towards 
different cancer types. Thus, we decided to investigate the role of azurin in interfering with the 
capacity of cancer cells to adhere to several ECM components, by performing adhesion assays 
to different ECM components (laminin-332, collagen type-I, fibronectin and collagen type-IV). 
Also, as integrins are major receptors in this process, we went to investigate the expression of 
these proteins by western blot, using different biological matrices (collagen type-I matrix and 
Matrigel
TM
). As previously proved for other models, we also performed a gelatine zymography to 
determine MMP-2 activity and Matrigel
TM
 invasion assays to evaluate the impact of azurin in the 
invasion process in different cancer models. 
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5. Materials and methods 
 
5.1. Cell lines and cell cultures 
 
Four human breast cancer cell models have been used in this study: MCF7/AZ [kindly 
provided by Doctor Joana Paredes (IPATIMUP) in the context of a collaborative ongoing project; 
MCF7/AZ.Mock and MCF7/AZ.Pcad were stably transduced with empty vector (control) or 
CDH3/P-cadherin cDNA, respectively], BT-20 and SUM-149 [kindly provided by Prof. Stephen 
Ethier (University of 161 Michigan, MI, USA), constitutively express high levels of P-cadherin]; 
one lung cancer cell line A-549; and mouse macrophages J774. 
MCF7/AZ.Pcad, MCF7/AZ.Mock and BT-20 were routinely maintained in  DMEM, SUM149 
in DMEM-F12 (1:1 v/v) and A-549 in F-12 (Gibco, Invitrogen Ltd, Paisley, UK); supplemented 
with 10% of heat-inactivated fetal bovine serum (FBS) (Lonza, Basel, Switzerland), 100 IU/mL 
penicillin and 100 mg/mL streptomycin (Invitrogen). SUM-149 medium was supplemented with 1 
µg/mL hydrocortisone and 5 µg/mL insulin (Sigma-Aldrich-Aldrich, St. Louis, MO, USA). J774 
was maintained in DMEM (Gibco, Invitrogen Ltd, Paisley, UK) supplemented with 10% FBS, 
100 IU/mL penicillin and 100 mg/mL streptomycin (Invitrogen). Cells were grown at 37ºC in a 
humidified chamber containing 5% CO2 (Binder CO2 incubator C150). 
 
5.2. Bacteria growth, over-expression, extraction and purification of azurin 
 
To perform the pre-inoculum, 100 mL of LB medium with 100 µL of 150 µg/mL ampicillin was 
inoculated over-night with Escherichia coli SURE (cloned with the plasmid pWH844, containing 
the gene azu, from Pseudomonas aeruginosa PAO 1, responsible for the synthesis of azurin) 
(Bernardes et al., 2013) at 37 ºC in an agitator at 250 rpm. The following day, the inoculum was 
made with the pre-inoculum at OD640 0.1 in 1 L of SB medium (3.2% tryptone, 2% yeast extract 
and 0.5% NaCl) with 150 µg/mL ampicillin at 30-37 ºC in an agitator at 250 rpm. The culture 
was grown until OD640 0.6-0.8, and protein expression was induced with 0.2 mM IPTG. The 
culture was grown during 5 hours at 30-37 ºC in an agitator at 250 rpm. Cells were collected 
after centrifuge the culture at 8000 rpm at 4ºC during 10 minutes (Beckman J2-MC Centrifuge), 
and the pellets were ressuspended in 15 mL of START buffer (10 mM imidazole, 0.2 mM 
sodium phosphate, 0.5 M NaCl, pH 7.4) and stored at -80 ºC until purification. 
For purification, cells were sonicated (Branson Sonifier Sound Enclosure) and centrifuged at 
17600 g at 4º C during 5 minutes (B. Braun Sigma-Aldrich 2K15). To remove debris, the 
supernatant was again centrifuged during 1 hour. Protein was purified in a histidine affinity 
column (HisTrap
TM
 FF, GE Healthcare) and eluated with increased concentrations of imidazole 
(20-500 mM). Azurin is eluted with 100-200 mM of imidazole. Afterwards, buffer was exchanged 
to PBS in ÄKTA system (ÄKTA Prime, Amersham Biosciences) with a desalting column 
(HiPrep
TM
 26/10 Desalting, GE Healthcare), following the manufacturer’s instructions. After 
injection of the sample and elution, protein was collected and centrifuged in a 3 kDa cut-off 
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column (Amicon Ultra Centrifugal Filter, Ultracel 3K, Milipore) at 5000 rpm at 4 ºC (Eppendorf 
Centrifuge 5804R), to concentrate the sample. Protein was then passed through a detoxing 
column (Detoxi-Gel
TM
 Endotoxin Removing Column, Thermo Scientific) to remove endotoxins 
from E. coli host strain; and centrifuged again in a falcon with a 3 kDa cut-off to concentrate. 
The concentration was calculated after reading the absorbance at 280 nm, and using Beer-
Lambert equation, where ε(280)=9.1 x 10
3
 M
-1
.cm
-1
 [Abs - absorbance, ε - extinction coefficient 
(M
-1
.cm
-1
), l coverage (mol.cm
−2
) and [azurin] – concentration of azurin] (van Amsterdam et al., 
2002). 
To verify any contamination, test spot (two spot with 10µL of azurin in a LB agar plate) was 
performed over-night at 37 ºC. Azurin was kept at 4 ºC until further use. 
  
5.3. Protein extraction and western blot 
 
Matrix coating [collagen type-I matrix (08-115, Millipode) or Matrigel
TM
 (BD Matrigel
TM 
Basement Membrane Matrix, BD Biosciences)] was performed in 6-well plate (200 µL/well). 
After 2 hours at 37 ºC, cells were plated with 5x10
5
 cells (MCF7/AZ.Pcad and MCF7/AZ.Mock) 
or 7.5x10
5
 cells (SUM-149 and BT-20). The following day, cells were treated with azurin (50-100 
µM) in complete medium. 
Cancer cells untreated or treated with azurin were washed twice with PBS, lysed in 100 µL of 
catenin lysis buffer (1% Triton X-100, 1 % Nonidet-P40 in deionized PBS) with 1:100 
phosphatases inhibitor (Cocktail 3, Sigma-Aldrich) and 1:7 proteases inhibitor (Roche 
Diagnostics GmbH, Germany) and after 10 minutes at 4 ºC were scratched). The lysates were 
collected, vortexed three times and centrifuged at 14,000 rpm at 4 ºC for 10 minutes (B.Braun 
Sigma-Aldrich 2K15) and quantified by BCA method (BioRad Protein Assay). 20 µg of total 
protein per sample were prepared, denatured at 95ºC during 5 minutes, and then separated by 
electrophoresis in a SDS-PAGE (Table 3). 
  
Table 3: SDS-PAGE 
 Gel Resolving 8% Gel Resolving 15% Gel Stacking 5% 
H2O 2.3 mL 850 µL 1.35 mL 
30% Acrilamide 1.35 mL 1.9 mL 335 µL 
Tris 1.25 mL (1.5 M) 950 µL (1.5 M) 250 µL (1 M) 
10 % SDS 50 µL 34 µL 20 µL 
APS 50 µL 34 µL 20 µL 
TEMED 3 µL 1.5 µL 2 µL 
 
Gels were transferred onto nitrocellulose membranes (RTA Transfer Kit, BioRad), using 
Trans-Blot Turbo Transfer System (BioRad), following manufacturer’s instructions.  After 
blocking the non-specific binding sites for 1 hour with 5% (w/v) non-fat dry milk in PBS-tween-20 
(0.5% v/v), the membranes were incubated in a agitator overnight at 4 ºC with different primary 
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antibodies (anti-E-cadherin [HECD 1, Sigma-Aldrich], anti-azurin [AB0048-200 SicGen] and 
anti-actin [sc-1616, Santa Cruz Biotecnology] diluted 1:1000 in 5% non-fat milk; anti-P-cadherin 
[clone 56, BD Transduction Laboratories] diluted 1:500, and anti-integrins [α6, sc-13542, β1, sc-
18887; β4, sc-6629, Santa Cruz Biotecnology] diluted 1:200). 
The membranes were washed three times with PBS-tween-20 (0.5% v/v) for 5 minutes and 
probed with the appropriated secondary antibody, conjugated with horseradish peroxidase [anti-
mouse (sc-2005, Santa Cruz Biotecnology) for cadherins and integrins, and anti-goat (sc-2354, 
Santa Cruz Biotecnology) for azurin and actin, diluted 1:2000 in 0.5% PBS tween-20] at room 
temperature for 1 hour, in an agitator. After washed, the membranes were developed by adding 
ECL substrates (Pierce) and capture the chemiluminescence by Fusion Solo (Vilber Lourmat) 
equipment.  The band intensity was measured using ImageJ and results are present as the ratio 
between the signal intensities in azurin treated samples to untreated cells. The protein levels 
were normalized by the respective actin level. 
   
5.4. Adhesion assay to ECM components 
 
Cells were plated in 6-well plates with 5x10
5
 cells (MCF7/AZ.Mock and MCF7/AZ.Pcad) or 
7.5x10
5
 cells (SUM 149 and A-549) and left to adhere. The following day, cells were treated with 
azurin in complete medium supplemented with 10% FBS. For each cell line, three conditions 
were analyzed: 0 µM (control), 50 µM and 100 µM of azurin. 
Different proteins from the ECM [laminin-332 (Sigma-Aldrich), collagen type-I (Millipode) and 
-IV (Sigma-Aldrich), and fibronectin (Sigma-Aldrich)] at 5 µg/mL diluted in sterile PBS were 
coated in a 96-well plates (over-night at 4 ºC); and BSA 0.5% and plastic were used as controls. 
Before addition of cells, plates were washed three times with sterile PBS containing PenStrep 
(Invitrogen) and non-specific binding sites were blocked with 0.5% BSA during 2 hours at 37 ºC.  
Azurin treated and control cells were washed twice with sterile PBS, collected with trypsine, 
and ressuspended in complete medium supplemented with 10% FBS. After centrifuged at 1200 
rpm during 5 minutes (Eppendorf Centrifuge 5702R), cells were washed twice with PBS, 
ressuspend in simple medium. Cells (100 µL at the density of 10
6
 cells/mL) were plated in the 
96-well coating plates and left to adhere to the different ECM components, during 30 minutes at 
room temperature. Cells were washed three times with PBS to remove non-adherent cells, 
attached cells were fixed with 4% paraformaldehyde and stained with 1% crystal violet (0.25 
mM crystal violet, 20% ethanol, 56.3 mM ammonium oxalate) during 10 minutes at room 
temperature. After washed excessive dye twice with PBS, the dye was dissolved in 200 µL of 
100% ethanol. The absorbance was read at 570 nm to quantify crystal violet staining. The 
analysis of the adhesion assay was made using control absorbance as 100% of staining, 
meaning 100% of adhesion. 
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5.5. Immunocytochemistry 
 
MCF7/AZ.Pcad cells were seeded on a round glass coverslip in 24-well plates with 5x10
4
 
cells and left to adhere in a CO2 incubator at 37ºC. The following day, cells were treated with 
azurin in complete medium. Three conditions were analysed: 0 µM (control), 50 µM and 100 µM 
of azurin. 
After 48 hours, coverslips were rinsed with PBS three times. For fixation, cells in coverslips 
were immersed in 4% formaldehyde for 20 minutes at room temperature. After wash three times 
in PBS, cells in coverslips were immersed in ammonium chloride (50 mM in PBS) for 10 minutes 
at room temperature. After washed three times in PBS, cells in coverslips were immersed in 
0.2% Triton X-100 (Sigma) for 5 minutes at room temperature, to achieve permeabilization. For 
immunostaining, cells in coverslips were blocked with 5% BSA in PBS at room temperature 
during 30 minutes. Without washing, BSA excess was removed and cells were incubated with 
primary antibody (1:50 anti-integrins) during 1-2 hours, in the dark at room temperature, wash 
three times in PBS and incubated in 1:500 secondary antibody (Alexa Fluor 488 anti-mouse or 
anti-goat, Invitrogen) during 1 hour, in the dark at room temperature. After washed three times 
in PBS, cells in coverslips were mounted with Vectashield with DAPI (Vector Inc., Burlingame, 
CA, USA) and observed in confocal microscope (Zeiss).  
 
5.6. ROS measurement 
 
Cells were seeded 2x10
4
/well (MCF7/AZ.Pcad and MCF7/AZ.Mock) or 5x10
4
/well (SUM 149 
and J774) in phenol-red free medium in 96-well black plates for 24 hours at 37 ºC and 5% CO2. 
The following day, the medium was aspirated and cells were washed twice in PBS. Cells were 
treated with azurin in DMEM phenol-red free medium (Gibco, Invitrogen Ltd, Paisley, UK) during 
24 hours (SUM 149 and J774) or 48 hours (MCF7/AZ.Pcad and MCF7/AZ.Mock). After washed 
twice with PBS, cells were exposed to 2',7'-diclorodihydrofluorescein di-acetate (DCFH-DA, 10 
µM) during 30 minutes at 37 ºC and 5% CO2. DCFH-DA was aspirated and cells were washed 
twice with PBS. Finally, 200 µL/well of PBS were added and fluorescence intensity was read 
(Software SoftMax Pro 6.1) with excitation wavelength of 485 nm and emission wavelength of 
535 nm (FilterMax F5 Multi-Mode Microplate Reader, Molecular Devices).  
 
5.7. Gelatine zymography 
 
Cells were seeded in collagen type-I in 6-well plates. Cell conditioned media were collected 
and centrifuged at 1200 rpm at 4 ºC during 5 minutes (Eppendorf Centrifuge 5702R) to remove 
cell’s contaminations. Equal volumes of samples were prepared and added to zymography 
buffer (0.25 M Tris, 10% SDS, 4% sucrose, 0.03% bromophenol blue, pH 6.8). After perform an 
electrophoresis using a 10% polyacrylamide gel containing 0.1% gelatine (Sigma-Aldrich) at 80 
V, the gel was washed twice in 2% Triton X-100 (Sigma-Aldrich) during 30 minutes at room 
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temperature to remove SDS. The gel was left over-night (~16 hours) in gelatine reaction buffer 
(0.2 M NaCl, 4 mM CaCl2, 50 mM Tris, 1% Triton X-100, pH 7.4) at 37ºC in a gently agitation 
(60 rpm). Gelatine reaction buffer was discarded and stained with Coomassie Blue Staining 
Solution [0.1% Coomassie Blue R250 in 10% acetic acid solution and 40% (v/v) methanol] 
during 30 minutes. After destained (20% methanol and 10% acetic acid), both active and 
inactive forms of the MMP-2 can be visualized (white band on a blue background), according to 
the molecular weight. 
 
5.8. Matrigel
TM
 invasion assay 
 
Matrigel
TM
 invasion assay was performed using BD Biocoat Matrigel
TM
 Invasion Chambers 
with 8 micron pore size PET membrane with a thin Matrigel
TM
 layer (BD Biosciences), following 
manufacturer’s instructions. Briefly, chambers were pre-incubated with serum-free medium 
during 2 hours at 37 ºC. In the upper compartment of the chamber 2x10
4
 (A-549) or 2.5x10
4
 
(BT-20) cells were added in completed medium and in the lower compartment only complete 
medium. After 48h (A-549) or 24h (BT-20) at 37ºC, non-invasive cells were cleared chambers 
were washed with PBS (four times). Cells were fixed in cold methanol during 10 minutes at 4ºC.  
Invasive cells attached to the lower surface were stained with DAPI and counted under the 
microscope (Zeiss). Invasion index is express compared with control (untreated).  
 
5.9. Statistical analysis 
 
For in vitro experiments, at least one independent replicate were performed (n=1 to 4 
sample/experiment). Experiment performed once was considered preliminary results 
($:preliminary results). All p-values were calculated using Student’s t-test (two-tailed distribution, 
two-sample equal variance). Values of p<0.05 were considered statistically significant (*:p<0.05) 
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6. Results 
 
Azurin decreases adhesion of breast cancer cell lines to ECM components 
 
As described in the objectives section, after a microarrays analysis of MCF7.AZ/Pcad cell 
line treated with azurin (100µm, 48h), biological, cell-cell and cell-matrix adhesion were groups 
that were enriched in the genes down-regulated by azurin (Bernardes et al., 2013). To verify 
those alterations induced by azurin, we performed adhesion assays to different ECM 
components (laminin-332, collagen type-I, fibronectin and collagen type-IV), using BSA and 
plastic coating as controls. Cells were treated with azurin in standard plastic culture, and left to 
adhere during 30 minutes to the different components. Afterwards, adhesion was quantified by 
the violet-crystal method. 
 
As we can see in Figure 14, in the MCF7.AZ/Pcad cell line, azurin decreased the adhesion 
to ECM components, when compared with untreated cells. This effect is more marked after 48h 
treatment compared with 24h treatment; and also in laminin-332 or collagen type-I (20% less of 
adhesion) and fibronectin (10% less of adhesion). 
 
 
Figure 14: Adhesion assays in breast cancer cells (MCF7.AZ/Pcad). MCF7.AZ/Pcad treated 
with azurin during 24h (A) and 48h (B); all were let to adhere during 30min in different ECM 
components (*: p<0.05). 
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In the MCF7.AZ/Mock, this effect (in laminin-332 or collagen type-I) is also observed but only 
with the higher concentration of azurin and only after 48h of treatment. 
Since it had already been demonstrated that azurin can also lead to a decrease in the invasion 
and P-cadherin levels in SUM149 breast cancer cell model (Bernardes et al., 2013), we also 
performed adhesion assays in this breast cancer cell line (Figure 15), showing also that azurin 
decreased cell-matrix adhesion, mainly in laminin-332 and collagen type-IV (in a dose-
dependent manner), with a decreased of 20-30% and 10-15%, respectively. A decreased was 
also observed in fibronectin (less 10% of adhesion) but only with significantly with the lower 
concentration of azurin. 
 
 
Figure 15: Adhesion assays in breast cancer cell lines (MCF.AZ/Mock and SUM149). 
MCF.AZ/Mock treated with azurin during 48h (A) and SUM149 treated with azurin during 24h 
(B); all were let to adhere during 30min in different ECM components (*: p<0.05).  
 
Together these results suggest that azurin decreases the adhesion of cancer cells to ECM 
components, in P-cadherin over-expressing breast cancer, mainly in laminin-332 and collagen 
matrices. 
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Azurin alters integrins expression in breast cancer cell lines 
 
The ability of azurin to decrease cell adhesion to ECM components could be dependent on 
alterations in integrin receptors. Furthermore, it has been demonstrated that in basal-like breast 
cancers, P-cadherin is co-expressed with CD49f (integrin subunit α6) (Vieira et al., 2012). For 
those reasons, we performed Western blot analysis to identify possible alterations of relevant 
integrin subunits. We looked to the expression of anti- integrin subunits α6-, β1- and β4 due to 
the fact that β1-intergin is one of the most common integrin subunits present in heterodimers, 
and subunits α6 and β4 are more specific to laminin  and the mostly expressed in normal 
mammary tissue. Both integrins α6β4, α6β1 have been previously associated with breast cancer 
migration and invasion (Koistinen & Heino, 2000; Mizejewski, 1999). 
In MCF7.AZ/Pcad cell line, results about integrin subunit α6 are irregular. In plastic 
conditions, azurin treatments seem to maintain or even increase integrin subunit α6 (Figure 16). 
However, in collagen type-I and Matrigel
TM
 matrices, azurin decreases the expression integrin 
subunit α6 about 30% related to untreated protein levels. This reinforces the importance of 
mimic the real tumour microenvironment. Also, integrin subunits β1 and β4 are decreased by 
azurin when cells were cultured in collagen type-I and Matrigel
TM
 matrices: 40-60% in plastic 
and 50% in Matrigel
TM
 in integrin subunit β1 level, and 25% in plastic and 20-40% in collagen 
type-I in integrin subunit β4 level. However, in plastic conditions, in the lower concentration of 
azurin, we observed an increase in integrin subunit β1 level, which was not observed in a higher 
concentration, which could be due to an experimental error or to a different mechanism that 
cells use to compensate the entry of azurin, that was no longer tolerated to the higher 
concentration, as observed in cells cultured on top of the protein matrices used.  
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Figure 16: Azurin decreases protein expression of integrins (MCF-7/AZ.Pcad). MCF-7/AZ.Pcad 
were treated with azurin (50μM and 100μM) during 48h in plastic conditions, collagen type-I 
matrix or Matrigel
TM
 (*: p<0.05). 
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By immunocytochemistry it was possible to verify that azurin decreases integrin subunits 
levels and membrane localizations, using MCF-7/AZ.Pcad cell line (Figure 17). In untreated 
cells, integrin subunits α6 and β1 are localized in the membrane of the cell, however, after 
treatments with azurin, integrins are no longer in membrane and it seem to be 
compartmentalised inside the cells.  
 
 
Figure 17: Azurin decreases integrin subunits and re-localized in MCF-7/AZ.Pcad cell line. 
 
In SUM149 cell line (Figure 18), integrin subunit α6 levels decreases significantly in plastic 
(45-80%), in collagen type-I (30-40%) and Matrigel
TM
 (40%). integrin subunit β1 levels also 
decreases, about 20-60% in plastic and 50% in Matrigel
TM
. integrin subunit β4 level decrease 
50% in plastic and seems to decrease in collagen type-I. However, integrin subunit β4 level 
increases 50% in Matrigel
TM
.  
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Figure 18: Azurin decreases protein expression of integrins (SUM149). SUM149 were treated 
with azurin (50μM and 100μM) during 24h in plastic, collagen type-I matrix or Matrigel
TM
 (*: 
p<0.05). 
 
Together these results suggest that azurin decreased these integrin subunits levels. 
However, in MCF7.AZ/Pcad cell line integrin subunit α6 seems to increase and in SUM 149 
integrin subunit β4 level seems to increase. In both breast cancer cell lines with P-cadherin over-
expression, integrin subunit β1 level decrease, suggesting that it is very important in breast 
cancer progression. 
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Azurin alters ROS production 
 
ROS, and consequently oxidative stress and apoptosis via p53, may regulate integrin-
mediated cellular response (ex: cell adhesion and migration). Caveolae/lipid rafts, focal 
adhesions and cell-cell contacts can target and activate NADPH oxidases, leading to ROS 
production and redox signalling. But also, integrin activation, in turn, increases ROS production 
(Goitre et al., 2012). Using N-acetylcysteine, an anti-oxidant, hydrogen peroxide, which is a 
ROS, decreased and, consequently, also cell adhesion, proving that ROS production has a role 
in the signalling cascade triggered by integrins during cell-ECM interactions. Also, ROS 
production is mediated in part by the up-regulation of FAK (a pathway that induces cell 
adhesion) (Chiarugi et al., 2003). ROS regulation could be a potential target to cancer therapy 
through impairment of cell adhesion receptors (Goitre et al., 2012). 
 
For that reason, ROS production was measured in the absence/presence of azurin (Figure 
19). MCF7/AZ cell lines were exposed during 48h; and SUM149 and J774 during 24h (time of 
treatment depended on the cell line and the observed P-cadherin alteration (Bernardes et al., 
2013). As a positive control we used macrophages J774, where it had been previously showed 
that azurin induces ROS production (Yamada et al., 2002b). As seen in the previous sections, 
azurin can decrease cell-matrix adhesion and integrin levels, suggesting that the decrease of 
ROS production (and oxidative stress) observed in MCF7.AZ/Pcad and MCF7.AZ/Mock is 
through NADPH oxidases inactivation. In fact, in the referred microarray analysis indicate a 
reduced expression of NADPH and others genes related with oxidative stress (unpublished 
data). 
Because we observed in both MCF7.AZ a significantly decrease of ROS production, it is 
possible that ROS decreased is independent of P-cadherin. Also, as previously showed, azurin 
decreased FAK/Scr signalling (Bernardes et al., 2013), so it may be possible that azurin acts 
ROS-dependent manner in MCF7.AZ mediated by FAK/Src signalling. However, SUM149 
showed an increase of ROS production with azurin, suggesting that azurin can induce different 
pathways of actions. Probably, due to the fact that MCF7 breast cancer cell line is basal-like and 
SUM149 breast cancer cell line is luminal-like. To deepen, ROS measurement should be done 
in BT-20 (another basal-like breast cancer cell line) and A549 (lung cancer cell line). 
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Figure 19: ROS measurement in breast cancer cells. MCF7.AZ/Pcad (A) and MCF.AZ/Mock (B) 
treated with azurin during 48h, SUM149 (C) and J774 (D) treated with azurin during 24h (D) (*: 
p<0.05).  
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Azurin alters integrins expression, invasion capacity and MMP activity in BT-20 cell line 
 
To validate these results, we used another P-cadherin over-expressing breast cancer cell 
line, BT-20. This cell line was previously assessed for the anticancer activity of azurin, and cells 
were treated plastic growth conditions, however, in that conditions, no alterations were found in 
P-cadherin levels upon treatment. However, growing cells in a collagen type-I matrix or 
Matrigel
TM
, azurin had an impact at this protein expression levels as well as at integrin subunits 
(Figure 20). 
 
 
 
Figure 20: Azurin decreases P-cadherin in ECM components but not plastic (BT-20). BT-20 
were treated with azurin (50μM and 100μM) during 24h in plastic conditions, collagen type-I 
matrix or Matrigel
TM
 ($: preliminary results). 
 
As seen in Figure 21, on BT-20 breast cancer cell line, integrin subunit α6 levels decreased 
in collagen type-I and Matrigel
TM
 matrices; integrin subunit β1 level decreases 50% with the 
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higher concentration of azurin used (100µM); and integrin subunit β4 levels increase in collagen 
type-I and decrease 20% in Matrigel
TM
. The result more significant and consistent is the 
decrease in integrin subunit β1 level. 
 
 
 
Figure 21: Azurin decreases protein expression of integrins (BT-20). BT-20 were treated with 
azurin (50μM and 100μM) during 24h in plastic conditions, collagen type-I matrix or Matrigel
TM
 
(*: p<0.05; $: preliminary results). 
 
It has been previously demonstrated that P-cadherin-induced invasion is mediated, at least 
in part, by the secretion of MMP-1/-2 to the extracellular media (Ribeiro et al., 2010). In MCF-
7/AZ.Pcad and SUM149 cells, azurin induce a decrease in MMP-2 activity (Bernardes et al., 
2013). In order to perform that analysis, cells are gown in a collagen type-I matrix, to maximize 
MMPs secretion. Taking our previous results into account, we also analyzed if in BT-20 cell line, 
azurin also produced the same effect. Indeed, also, azurin decreases MMP-2 activity in BT-20 
(Figure 22). 
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Figure 22: Gelatine zymography (BT-20). BT-20 cells grown in collagen type-I matrix, 
conditioned medium were used to observed MMPs activity ($: preliminary results). 
 
BT-20 cell line is also a breast cancer cell line over-expressing P-cadherin, like MCF7-
AZ/Pcad and SUM149, and in all three integrin subunit β1 level decrease, reinforcing the 
importance of integrin subunit β1 in cancer progression, like in invasion.  
Beyond the decrease in MMP-2 activity, our group has also showed that azurin decreases 
invasion of P-cadherin over-expressing breast cancer cells (Figure 23). With the lower 
concentration of azurin (50µM), the invasion capacity of BT-20 decreased 20% and about 45% 
when cells were treated with 100µM. This is consistent with invasion results in MCF-7/AZ.Pcad 
and SUM149 cells, with a reduction of 66% and 44% of invasion, respectively (Bernardes et al., 
2013).  
Together these results indicate that azurin in BT-20 decrease integrins (involved in 
adhesion), invasion capacity and MMP activity (involved in migration). 
 
 
Figure 23: Invasion assay in Matrigel
TM
 (BT-20). BT-20 cells were treated with azurin during 
48h (*: p<0.05; $: preliminary results).   
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Azurin alters adhesion to ECM components, invasion and integrins expression in A549 
lung cancer cell line 
 
To identify some general impact of azurin in other cancer cell models, A549 non-small cell 
lung cancer was treated with azurin during 48h to evaluate some of the effects identified in the 
previous models. A decrease, in a depend-dose manner, in adhesion to ECM components was 
observed in all matrices, with statistical significance in collagen type-I (decrease of 20-60%), in 
fibronectin (decrease of 60%) and in collagen type-IV (decrease of 30%) (Figure 24).  
 
 
Figure 24: Azurin decreases adhesion in different ECM components (A549). A549 lung cancer 
cell line were treated with azurin during 48h and let to adhere during 30min in different ECM 
components (*: p<0.05). 
 
We analyzed by western blot some of the relevant protein in cell-cell adhesion (E-cadherin) 
and cell-to-matrix adhesion (integrin subunit β1) (Figure 25). A549 exhibits high E-cadherin 
expression but no detectable P-cadherin expression (Zhang et al., 2010). For that reason, we 
only evaluate E-cadherin expression. 
We observed an increase in E-cadherin levels upon azurin treatment and a decrease of 
integrin subunit β1 level (cell-matrix adhesion). In this cell line, increased integrin subunit β1 is 
correlated with decreased overall survival and recurrence-free survival (Yao et al., 2007). A 
study reveals that lung metastasis in integrin subunit β1 deficient mice revealed a two-fold 
reduction in the number of mice that developed metastasis and a six-fold reduction in the 
number of metastasis; and also a reduction of cell survival and angiogenic infiltration. 
Understanding the role and influence of each specific heterodimer in mammary tumourigenesis 
might be essential to develop a more selective therapeutic approach like of integrin subunit β1 
inhibitor (Lahlou & Muller, 2011). 
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Figure 25: Azurin decreases protein expression of E-cadherin and integrin subunit β1 (A549). 
A549 were treated with azurin (50μM and 100μM) during 48h in plastic conditions or collagen 
type-I matrix (*: p<0.05; $: preliminary results). 
 
Also, and although preliminary, we analyzed the activity of MMP-2 and invasion through 
Matrigel
TM
, as functional consequences of treating these cells with azurin (Figure 26). We 
observed an decrease of MMP-9 active form activity and a 25-40% decreased of invasion 
capacity was observed. Altogether, these results suggest that azurin has an impact in integrin 
subunit β1, adhesion and invasion in non small cell lung cancer, suggesting that these 
phenomena are a broad line of action of this anticancer bacterial protein despite the tumour 
origin. 
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Figure 26: Azurin decreases MMP-2 activity and invasion capacity (A549). (A) Gelatine 
zymography, cells grown in collagen type-I matrix, conditioned medium were used to observed 
MMPs activity. (B) Invasion assay in Matrigel
TM
, cells were treated with azurin during 48h. ($: 
preliminary results). 
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7. General discussion 
 
P-cadherin expression in breast carcinomas is a marker of poor survival (Paredes et al., 
2007). On one hand, P-cadherin interferes with the normal invasive suppressive function of E-
cadherin; on the other hand, there is no targeted therapy to this protein. For that reason, azurin 
was used to target P-cadherin, decreasing its level in P-cadherin over-expressing breast cancer 
models (Bernardes et al., 2013). However, the mechanism of action of azurin is not well known. 
After treat MCF-7/AZ-Pcad cell line with azurin during 48 hours, a microarrays analysis was 
performed in which biological adhesion and cell-cell adhesion were two groups of genes that 
are down-regulated (Bernardes et al., 2013, submitted). 
Not much is known about how the stromal microenvironment at metastasis sites provides a 
suitable home to tumour cells. It is important to study the interaction between metastatic cells 
and niche cells, and between metastatic cells and ECM (Muschler & Streuli, 2010). The ECM of 
the basement membrane acts as a barrier and also as helper for cancer cells to migrate 
(Tsuruta et al., 2008). For that reason, understanding the interaction with the microenvironment 
is extremely important. 
 
In order to achieve a functional validation of the microarrays analysis, adhesion assays were 
performed to understand if azurin can alter cell adhesion to different ECM components (laminin-
332, collagen type-I, fibronectin and collagen type-IV). For that, four breast cell lines expressing 
different level of P-cadherin were used: MCF-7/AZ.Mock and MCF-7/AZ.Pcad (p53 wild type), 
SUM149 and BT-20 (constitutively over-expresses P-cadherin and mutant p53) and A549 
NCCLC cell line. In general, azurin decreased adhesion to all ECM components, but more 
significantly to collagen type-I and laminin (breast cancer) and fibronectin (lung cancer). In fact, 
in the mammary gland, the main ECM components found are laminin and collagen (Tsuruta et 
al., 2008) and, in lung microenvironment, is fibronectin (Ritzenthaler, Han, & Roman, 2008). 
Luminal cells contacting the stromal ECM, such as collagen type-I, is a feature known to lead 
to signalling into aberrant transformations, up-regulation of MMPs, invasion and metastasis 
(Bissell et al., 2011). Targeting cell-matrix interaction could improve cancer therapy; such as 
matrix-degrading proteases inhibitors (target ECM modifications) and integrins inhibitors (target 
angiogenesis inhibition). Target integrins can enhance the responsiveness of breast tumour 
cells to radiation and Her-2 targeting. The targeting of cell-ECM interaction could be a standard 
component of the oncologist’s therapeutic arsenal (Muschler & Streuli, 2010). 
 
Because integrins are the main receptors in adhesion process and because CD49f (integrin 
subunit α6) is co-expressed with P-cadherin (Vieira et al., 2012), western blots were done to 
understand if azurin alters integrin subunits levels. In MCF-7/AZ.Pcad and SUM149, azurin 
decreased integrin subunits levels (α6, β1 and β4). However, in MCF7.AZ/Pcad cell line integrin 
subunit α6 seems to increase and in SUM 149 integrin subunit β4 level seems to increase. In 
both P-cadherin over-expressing breast cancer cell lines, integrin subunit β1 level decreased. 
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Also, in A549 lung cancer, integrin subunit β1 levels decreased. In previous studies, shikonin, an 
active naphthoquinone, showed effective anti-cancer activity both in vivo and in vitro. Shikonin 
suppresses lung cancer adhesion, invasion and metastasis by inhibiting integrin subunit β1 
expression and the phosphorylation of ERK1/2, decreasing this signaling pathway (Wang et al., 
2013). So, maybe azurin in A549 cell line reduces integrin subunit β1 level and adhesion via 
ERK. This hypothesis needs to be confirmed by western blot. 
The expression levels of integrin subunits α5, β1 and β3 predicted overall survival and 
disease free survival in NSCLC patients. For that, determining the integrin expression profile 
might serve as a tool in predicting the prognosis of individual patients (Dingemans et al., 2010). 
Together, these results suggest that different models with different characteristics and 
different microenvironment respond to azurin by the same signalling pathways through 
decreasing integrin subunit β1. For that azurin could be a potential anti-invasion drug through 
decreasing integrin subunit β1 levels. 
 
Integrin subunit β1 signalling has a crucial role for the focal adhesion kinase axis, due to the 
fact that integrin do not have enzymatic activity or actin binding domain. However, integrin 
subunit β1 is able to bind to partners (ex: talin, tensin) that allows cytoskeleton remodelling and 
activation signalling cascade (cell adhesion and motility), but also to FAK, paxillin and Src that 
allows a scaffold function. FAK, that have a central role in integrin subunit β1 signalling, is 
recruited by integrin subunit β1, where two NXXY motifs in C-terminal are important, inducing its 
auto-phosphorylation on Y397 and consequently recruitment of c-Src. integrin subunit β1 
controls the expression of oestrogen receptor α, and in turn oestrogen and progesterone 
regulate α5β1 expression. integrin subunits β1 and α6 are the only ones that are prove to be 
indispensable for appropriate mammary gland development (Lahlou & Muller, 2011). 
In 3D culture and in vivo, it has been shown that anti-integrin subunit β1 induces a dormant-
like phenotype, impairing proliferation but with a reversible effect (White & Muller, 2007). 
Integrin subunit β1, via uPA receptor and a complex containing FAK, in a fibronectin matrix 
induces cell proliferation through Ras-ERK pathway. Fibronectin:integrin:uPAR complex is 
required to reverse de dormant state. Curiously, integrins have two contradictory side, one in 
their role in dormancy (attenuating the cancer cell proliferation) and another by been a target to 
cancer therapy (White & Muller, 2007). 
Nevertheless, down-regulation of integrins does not mean that these integrin subunits are 
unimportant to malignant phenotype of cancer cells, because optimal migration and invasion 
depend on ligand concentration, integrins expression and ligand-integrin affinity (Koistinen & 
Heino, 2000). 
Recently, it was showed that dormant tumour cells may be resistant to chemotherapy and 
radiation. Integrin subunit β1 regulates the switch from a dormant state to active proliferation and 
metastasis. Like ATN-161, volociximab, and JSM6427 target  integrin subunit β1 signaling to 
aim dormant cancer cells (Barkan & Chambers, 2011), maybe azurin act in this same way. 
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Our group has previously demonstrated that phosphorylated FAK and its partner Src were 
decreased P-cadherin breast cancer models upon azurin treatment, concomitantly with 
decreased invasion and P-cadherin levels. FAK and Src are important non-RTKs that can be 
activated by integrin engagement by the ECM (Bernardes et al., 2013). So, azurin decreases 
integrin subunits levels, consequently it decreases phosphorylated FAK/ Src, that in turn 
decreases signaling, leading to a decreases of adhesion, invasion, migration and metastasis 
processes. 
 
Several tumourigenic processes are mediated by MMPs, namely the breakdown of 
extracellular components, which accounts greatly to the ability of tumour cells to invade the 
surrounding tissues through an extensive matrix remodelling. MMPs also promote the release of 
bioactive molecules able to induce invasion, like the cleavage of laminin-5 γ2 chains by MMP-2, 
producing a fragment containing an epidermal growth factor (EGF)-like domain, which induces 
integrin signaling and cell migration. We assessed the activity of MMP-2, by gelatine 
zymography, of BT-20 breast cancer cell line and A549 lung cancer cell line treated with azurin 
and could observed a decrease in its activity. An effect also observed in other P-cadherin over-
expressing breast cancer cell line (Bernardes et al., 2013).  
As previously showed, azurin decreased the invasion capacity in MCF-7/AZ.Pcad and 
SUM149 (Bernardes et al., 2013). Curiously, the effects on cell invasion seem to be related with 
a specific decrease in P-cadherin protein. This specificity shown for azurin effect on cadherins is 
very interesting, since P-cadherin expression is correlated to increased cell motility, cell 
migration and invasion (Bernardes et al., 2013, submitted). However, it is important to refer that 
this effect invasion capacity was observed not only in breast cancer cell models (MCF-7/AZ, 
SUM149 and BT-20) but in other distinct cancer cell model (A549 lung cancer), suggesting that 
azurin could be a potential therapeutic drug in different cancers, by its anti-invasion role, and 
consequently decreasing migration and metastasis processes. 
 
The loss of integrin-mediated cell–ECM contact results in an apoptotic process termed 
anoikis (Giannoni et al., 2008), and plays an essential role in the regulation of cancer cell 
metastasis (Rungtabnapa et al., 2010). However, cancer cells are able to resist to anoikis 
(Mizejewski, 1999). NF-κB promote integrin subunit β4 expression to mediate resistance to 
apoptosis and p63 induce integrin subunit β4 expression to mediate resistance to anoikis, via 
STAT3 (Pontier & Muller, 2009). Another study proved that cancer cells over-expressed laminin 
and integrin subunit β4, both promoting survival, leading to anoikis resistance too (Kim et al., 
2012). Also, cancer cells increases ROS level to promote survival and resistance to anoikis. 
Since azurin decreases integrin subunit β4 levels and ROS in MCF-7/AZ.Pcad, maybe cancer 
cells are less resistance to apoptosis and anoikis. A hypothesis that indicates that azurin is a 
possible new therapeutic strategy. 
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8. Main conclusions and future perspectives 
 
Azurin (50 µM and 100 µM) was used to treat breast cancer cell lines with distinct levels of 
P-cadherin expression and different invasive capacities (MCF-7/AZ.Mock, MCF-7/AZ.Pcad, 
SUM149, BT-20) and one non-small cell lung cancer (A549). We investigated the effect of 
azurin in cell adhesion to different ECM components (laminin-332, collagen type-I, fibronectin 
and collagen type-IV). We also quantified integrin subunits (α6, β1 and β4) expression by 
Western blot. The azurin effects was measured by others parameters, such as ROS 
measurement, immunocytochemistry, gelatine zymography to evaluate MMP-2 activity and 
invasion capacity. 
Azurin decreased integrin subunits (α6, β1 and β4) in all studied models (breast and lung 
cancer), but more consistently integrin subunit β1. Moreover, azurin decreases adhesion to all 
ECM components, but with more significance to collagen and laminin (breast cancer) and 
fibronectin (lung cancer), both main components in each cancer type. In BT-20 and A549, 
azurin decrease MMP-2 activity and consequently invasion capacity. All this is a functional 
validation of microarrays analysis performed in MCF-7/AZ.Pcad with azurin (100 µM, 48h) that 
corroborate that azurin is a potential cancer therapeutic drug. 
Together, these results suggest that different models with different characteristics and 
different microenvironment respond to azurin by the same signalling pathways through 
decreasing integrin subunit β1. For that azurin could be a potential anti-invasion drug through 
decreasing integrin subunit β1 levels. 
 
For following this particular work, in order to understand if azurin may have a general impact 
in integrins subunits in different cancer cells models, western blots in A549 lung cancer should 
be performed to investigate other subunits beyond integrin subunit β1. Integrin subunit β4 role in 
autophagy of lung adenocarcinoma cells is not clear. A study reveals that siRNA of β4 increases 
dead cells and level of p53; suggesting that integrin β4 is implicated in and associated with p53 
in autophagy of lung cancer cells (He et al., 2008). Also, immunocytochemistry should be done 
in all studies models to localize and visualise integrins subunits. 
 
Azurin (or its derived peptide - p28) penetrates in cancer cells faster than in normal cells 
(Yamada et al., 2005), by a mechanism that doesn’t cause plasma membrane disruption but 
depends on some of its components. For example, it is known that cholesterol removal from the 
plasma membrane of cancer cells, using methyl-β-cyclodextrin, significantly reduced the azurin 
entry (Yamada et al., 2009). After performing the microarray analysis of azurin treated breast 
cancer cells (MCF-7/AZ.Mock and MCF-7/AZ.Pcad) it was also revealed an up-regulation of 
genes associated vesicle transport and pathways associated with the lysosome, but also genes 
associated with endocytosis, membrane organization and endosome transport (Bernardes et al., 
2013). Protein degradation should be investigated to validate microarrays analysis, but also to 
identify the degradation pathway of integrins subunits. 
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Endocytosis and trafficking are also major mechanisms controlling signaling at the plasma 
membrane level. The mechanism by which azurin exerts its anti-cancer effects may depend on 
its route of cancer cell entry, disrupting caveolae and removing from the cell membrane 
selective receptors that may be over-activated. In cancer cells, the removal of functional 
receptors from cell surface and their targeting to lysosome was proven to be an important 
mechanism by which their permanent activation and consequent tumourigenesis is prevented, 
particularly to EGFR (Abella & Park, 2009). In anchorage-dependent cells, loss of integrin 
signaling stimulates caveolin-1 dependent internalization of lipid rafts (Rho GTPases, Erk, and 
PI3K) and transport to recycling endosomes, leading to a change in membrane organization 
(Norambuena & Schwartz, 2011). Caveolin-1 is a key protein involved in tumour metastasis. A 
study suggests that Cav-1 (down-regulated during cell detachment) plays a key role as a 
negative regulator of anoikis through ROS-dependent mechanism in human lung carcinoma 
(up-regulated during cell detachment) (Rungtabnapa et al., 2010). Also, EGFR represents the 
main target for non-small cell lung cancer therapy, like A549. A study reveals that integrin 
subunit β1-silenced cells show a defective activation of the EGFR signaling cascade, leading to 
decreased proliferation, migration and invasive behaviour. Integrin subunit β1 silencing might 
represent an adjuvant approach to anti-EGFR therapy (Morello et al., 2011). For those reasons, 
Cav-1 and EGFR level should be investigate by western blot (protein level) and qRT-PCR 
(mRNA level), in different cancer cells models and in different cancer cells models grown in 
different ECM components. 
Cell migration involves cycles of cell-matrix adhesion/detachment that is regulated by 
integrin-based focal adhesions. Integrin subunit β1 is internalized in a dynamin-dependent 
manner and it is need cholesterol and reduced lipid raft protein, caveolin-1. Furthermore, 
internalized integrin subunit β1 is co-localized with lipid rafts marker and is via dynamin-
dependent lipid raft-mediated pathway (Vassilieva et al., 2008). The results suggest that azurin 
target integrin subunit β1, so maybe azurin act via alteration of lipid raft. 
 
To deepen the subject about the impact of azurin in A549, PI3K should be evaluated by 
western blot to better understand signalling associated with integrins; ROS measurement 
should be done to evaluate oxidative stress level; and treatment only with methyl-β-cyclodextrin 
(that disturb lipid raft) should be performed to investigate if lipid raft affects integrins level. 
EGFR represents the main target for non-small cell lung cancer therapy, as its over-
expression or constitutive activation contributes to malignancy and correlates with poor 
prognosis. Integrin subunit β1 is required for propagating EGFR signaling. Silencing integrin 
subunit β1 decreases EGFR signalling, increases sensitivity to cisplatin and gefitinib and 
consequently impairs migration and invasive behaviour (Morello et al., 2011). Following this 
idea, synergetic potential of azurin with gefitinib (EGFR inhibitor used in NSCLC) should be 
assess. 
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This set of information will allow the better understanding the mechanism involved in azurin 
entry, but also accentuate the conclusions observed in breast cancer cell lines, to check an 
overall effect of azurin on cancer (independent of their origin), reinforcing the idea that azurin is 
a potential anti-invasive drug, by decreasing integrin subunit β1 and consequently the signalling 
involved.  
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